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Abstract 
 
Use of Omics Technologies to Address the Links between  
Environmental Exposures, Epigenetics, and Risk of Pediatric  
Obesity in a Mexican-American Population 
 
by  
 
Gwen Nicole Tindula 
 
Doctor of Philosophy in Environmental Health Sciences 
 
University of California, Berkeley 
 
Professor Nina Holland, Co-chair 
 
Professor John Balmes, Co-chair 
 
 
The alteration of gene expression mediated by epigenetic modifications has been proposed as a 
mechanism by which chemical and biological factors during gestation and childhood may 
influence health and adult disease onset. Changes in DNA methylation, the most commonly 
assessed epigenetic mechanism, have been linked to numerous exposures including diet, metals, 
and chemicals, such as phthalates. The majority of individuals, including pregnant women and 
children, have detectable levels of metabolites of phthalates, which are used in consumer 
products to increase flexibility of plastics and as solvents. Phthalate exposure during early life 
has been associated with poor birth and developmental health outcomes, which may be mediated 
by epigenetics. Increasing evidence in human and animal models has shown an association 
between exposure to phthalates and DNA methylation levels. However, there is limited research 
on the relationship between pregnancy phthalate exposure and imprinted gene methylation. 
Imprinted genes exhibit expression of one parental allele and many are involved in early growth 
and development.  
 
Progress in the field of metabolomics has allowed for the assessment of thousands of metabolites 
in biological specimens. Metabolomic levels in humans have been associated with age and 
obesity; however, research of the effect of metabolites, especially the diverse classes of lipid 
metabolites, on DNA methylation is sparse. Animal studies have identified associations between 
maternal fatty acid dietary supplementation and offspring DNA methylation. The relationship 
between maternal lipid metabolites and DNA methylation of newborns has only been examined 
thus far in 40 mother-child dyads from a predominantly Caucasian study population.   
 
Environmental exposures, in addition to their role in epigenetic regulation, have been shown to 
impact human health, such as obesity status. Despite advances in the identification of additional 
risk factors of obesity, the influence of maternal psychosocial factors on child obesity status and 
biomarkers has been poorly examined. 
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The aims of this dissertation are to address key knowledge gaps of the relationships of early life 
exposures, epigenetics, and childhood obesity. The analysis benefitted from numerous samples 
and longitudinal data accumulated since 1998 by the Center for the Health Assessment of 
Mothers and Children of Salinas (CHAMACOS) birth cohort study of hundreds of Mexican-
American children and their mothers. The well-documented environmental exposures and the 
high prevalence of parental and child obesity in the CHAMACOS population make this an 
excellent study population to assess the role of early life exposure on epigenetic mechanisms and 
health. Results from the research in this dissertation can inform public health prevention 
strategies in the general population and more targeted approaches in Hispanic subpopulations, 
which are projected to comprise a greater portion of the United States population in the 
upcoming decades.    
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CHAPTER 1. Aims and Organization of Dissertation 
 
Epigenetic modifications, specifically DNA methylation, have been proposed as a 
mechanism by which chemical, biological, and environmental factors during pregnancy and 
early development may influence disease etiology in adulthood. The research in this thesis 
examines the interplay between early life environmental exposure, newborn DNA methylation, 
and obesity status in the children from the CHAMACOS study. Pregnant mothers were enrolled 
in the study in 1998-2000, with the aim to assess the relationship between pesticide exposure and 
child development. Over the past 20 years, a wealth of demographic, exposure, and health data, 
as well as over 350,000 biological specimens, have been collected. This cohort, with a high 
prevalence of parental and child obesity and documented exposure to a wide array of 
environmental chemicals during pregnancy and early childhood, provides a unique opportunity 
to assess the effect of early life environmental exposures on DNA methylation, additional 
biomarkers, and child obesity status. The aims are as follows: 
 
Figure 1.1 Schematic of dissertation aims 
 
 
Specific Aims: 
 
Aim 1 (Chapter 3): To determine whether DNA methylation of imprinted genes in 
newborns is associated with phthalate exposure during gestation. We will assess the 
influence of prenatal exposure to phthalates, known endocrine disruptors, on DNA methylation 
of imprinted genes in cord blood. We will compare significant findings across DNA methylation 
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platforms and validate hits using expression analysis. Hypothesis: Early life exposure to 
phthalates is associated with modifications of newborn DNA methylation levels in imprinted 
genes, which are involved in biological pathways relevant to growth.   
 
Aim 2 (Chapter 4): To examine whether newborn genome-wide methylation levels are 
related to maternal lipidomic profiles during pregnancy. We will utilize data on 92 lipid 
metabolites measured in maternal plasma samples collected around 26 weeks gestation and 
determine if they are associated with methylation levels measured at over 450,000 CpG sites. 
Hypothesis: Maternal lipid metabolites, which are present in blood and can cross the placenta, 
are associated with newborn DNA methylation throughout the genome.    
 
Aim 3 (Chapter 5): To assess whether child obesity status is influenced by protective or 
adverse home environment factors. We will utilize data collected throughout childhood on 
maternal depressive symptoms and perceived social support, as well as assessment of the home 
learning environment. We will examine how these factors during early life contribute to child 
growth at ages 5, 9, and 14. Hypothesis: Increased maternal depressive symptoms, low perceived 
social support, and poor home environment are associated with suboptimal profiles of 
adiponectin and leptin, biomarkers of obesity, as well as obesity status.     
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CHAPTER 2. Background and Significance  
 
2.1 Environmental Epidemiology 
 The complexity of human diseases, including obesity, cannot be fully explained by 
genetic underpinnings, poor diet, or lifestyle factors. There is increasing interest in the role of 
environmental exposures in disease etiology, known as the field of environmental 
epidemiology1. An individual’s environment can include external toxicants, internal exposures 
(i.e. hormones), maternal-fetal interactions, and psychosocial factors1. Epigenetic influence on 
gene expression has recently emerged as a critical pathway explaining the impact of 
environmental exposures on various health outcomes2, 3. Epigenetic mechanisms regulate gene 
expression without changes in DNA sequence and include DNA methylation, histone 
modifications, and non-coding RNAs4. Epigenetic mechanisms, which are important in nuclear 
organization, transcription, genome stability, and imprinting control, can be used as biomarkers 
of exposure or disease1. 
 
2.2 Epigenetics and Health 
 Changes to epigenetic profiles have been related to numerous health outcomes, including 
cardiovascular disease5, autoimmune diseases6, 7, mental health status8-10, asthma11, and cancer12, 
13. Growing evidence in humans suggests that early life environmental exposures can impact 
epigenetic profiles and future disease risk2, 14. Specifically, the prenatal period has been 
identified as a particularly sensitive time for epigenetic disruption due to the two critical periods 
of establishment and modifications of epigenetic profiles accompanying fetal development15. 
The first period of epigenetic vulnerability occurs during the development of germline cells, 
which is accompanied by methylation re-programming and histone modifications15. The second 
takes place following fertilization, when the genome is demethylated and then remethylated2. 
Animal models have shown that environmental exposures can induce epigenetic changes, 
resulting in altered risk of diseases, such as obesity16.   
 
2.3 Child Obesity 
 Currently, development of obesity is primarily attributed to a caloric imbalance, where 
excess energy is stored as fat through adipogenesis, or inadequate physical activity. New 
evidence suggests that exposure to environmental factors, including chemical exposure, may 
play a role in the growing obesity epidemic17-19. Body mass index (BMI) is often used as an 
indicator of obesity. Children have obesity if their BMI is greater than the 95th percentile of the 
CDC sex-specific BMI-for-age growth charts20. Despite recognized limitations to using BMI to 
characterize obesity status (i.e. it does not capture abdominal fat), it is highly correlated with 
body fat measured by dual-energy X-ray absorptiometry, a more accurate but cost-prohibitive 
method in large study populations21. Childhood obesity been linked to asthma22-25, 
hypertension26, 27, and non-alcoholic fatty liver disease28. In addition, children diagnosed as 
obese have an increased likelihood of having obesity in adulthood, which is a risk factor for 
cardiovascular disease and type 2 diabetes29-31. 
 
2.4 DNA Methylation 
 DNA methylation is the epigenetic mechanism most commonly investigated and refers to 
the potential of a cytosine (C) base to be methylated at its 5th carbon if followed by a guanine (G) 
base in the DNA code, known as a CpG site. Roughly 30 million CpG sites are distributed 
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throughout the human genome, comprising the methylome, in regions known as CpG islands, 
shores, shelves, and gene bodies32. CpG islands refer to stretches of DNA with a high frequency 
of CpG dinucleotides, often located near the gene promoter, whereas shores and shelves are 
regions within 0-2 or 2-4 kb of CpG islands, respectively32. The genome also contains 
differentially methylated regions (DMRs), genomic regions where methylation patterns at 
several adjacent CpG sites differ33. DNA methylation patterns are reprogrammed during the 
prenatal period and may vary by tissue and cell type34. Gain of DNA methylation 
(hypermethylation) can result in gene silencing, while loss of methylation (hypomethylation) can 
lead to overexpression35, 36. 
 
2.5 Imprinted Genes and Epigenetic Regulation 
Recent studies have established the presence of approximately 100 imprinted genes 
within the human genome37. Genomic imprinting involves expression dependent on the parental 
origin of the allele38, 39. Specifically, in imprinted genes, only the paternal or maternal allele is 
expressed39. The determination of active versus inactive allele is regulated by DNA methylation 
established during the process of epigenetic reprogramming that occurs in developing gametes39. 
In imprinted genes, the term DMR is commonly used to refer to genomic regions with several 
adjacent CpG sites whose methylation is parent-of-origin-dependent (iDMRs) 40. 
 
2.6 Epigenetics and Environmental Exposures 
 The epigenome is simultaneously heritable, susceptible to environmental insult, and 
known to accumulate environmental effects throughout the life course4. A number of human 
studies have demonstrated the effects of environmental exposures on imprinted gene DNA 
methylation, including the influence of diet41-44, cigarette smoke45, maternal antibiotic use46, 
endocrine disrupting compounds47-49, metal exposure50-53, and maternal stress54, 55. Animal 
studies have shown altered methylation of imprinted gene DMRs related to chemical 
exposures56-60.  
Limited but growing evidence indicates that exposure to phthalates, a group of endocrine 
disrupting chemicals (EDC), is associated with DNA methylation changes14, 61, 62. Phthalates are 
a family of chemicals often found in consumer products, resulting in common exposure in the 
United States63, 64. Phthalates are often added to plastics to increase flexibility or are used as 
solvents in personal care products such as perfumes and lotions65. Common routes of exposure to 
phthalates, which are not chemically bound to their substrates and leach into the environment, 
include ingestion, dermal absorption, and inhalation65. Phthalate esters undergo quick 
metabolism and some have half-lives less than 24 hours66, 67. A majority of U.S. residents, 
including pregnant women, now have detectable concentrations of phthalate metabolites in their 
urine, considered the “gold-standard” for measurement of phthalate exposure63, 68. It appears that 
exposures are both chronic and pervasive66.  
Human studies have demonstrated associations between phthalate exposure before or 
during pregnancy and adverse impacts on health outcomes in children, including altered birth 
weight69-71, gestational age72, 73, pre-term birth74, 75, child growth and development76-78, child 
behavior79, respiratory health80, 81, and thyroid function82. A growing body of mechanistic, 
animal, and human data shows a strong link between phthalates and the biological pathways that 
influence obesity83. 
Epigenetic effects of phthalates on both global and site specific methylation have been 
observed in rodent studies62, 84, 85. However, research on the effects of phthalate exposure on 
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imprinted genes in humans is limited. Only two human studies have assessed the association 
between phthalate exposure during pregnancy and placental imprinted gene methylation. 
LaRocca et al. found that first trimester urine concentrations of low molecular weight (LMW) 
phthalate metabolites, as well as a summary measure of 11 phthalate metabolites, were inversely 
associated with placental H19 and IGF2 DNA methylation47. A study by Zhao et al. found that 
third trimester DEHP phthalate metabolite concentrations were inversely associated with IGF2 
DNA methylation in placenta samples49. Another study by Goodrich et al. examined the 
relationship between prenatal and childhood exposure to endocrine disrupting chemicals, 
including phthalates, and DNA methylation of two imprinted genes (H19, IGF2) in peri-
adolescents48. They found that third trimester phthalate metabolite levels of monobenzyl (MBzP) 
and mono-isobutyl (MiBP) phthalates in maternal urine samples were associated with H19 
hypermethylation in blood from 247 8-14 year old children, but this finding was attenuated to 
non-significance after adjustment for multiple testing. Currently, there is no data available on the 
relationship between cord blood imprinted gene methylation profiles and prenatal exposure to 
phthalates.  
  
2.7 Epigenetics and Obesity 
 Maternal obesity is a significant predictor of obesity in children86-88. The strong 
relationship between maternal and child obesity suggests a role for genetics and/or shared 
environmental factors. Changes in DNA methylation can affect the expression of genes involved 
in adipogenesis and metabolism, and this epigenetic dysregulation can be a critical pathway for 
obesity development in children89, 90. Several studies have observed site-specific differences in 
DNA methylation of obese vs non-obese subjects; however, they have been limited by small 
sample sizes91-94. Imprinted genes, which are regulated by DNA methylation, are valuable targets 
for study with respect to the early origins of obesity because they function as critical mediators 
of fetal growth95, 96. Researchers at Duke University have shown that paternal obesity in the 
NEST birth cohort is associated with hypomethylation at four iDMRs in newborns, including the 
insulin-like growth factor 2 (IGF2) iDMR, and maternal obesity was linked with changes in 
methylation at two iDMRs40, 97. Although sample size was limited, the data suggest that parental 
obesity can alter methylation at iDMRs, which can impact fetal growth and child development.  
 
2.8 Biological Markers of Obesity 
 Adiponectin and leptin are hormones that play an important role in the complex 
metabolic pathways related to obesity. The protein hormone adiponectin, which is primarily 
derived from adipose tissue, has anti-diabetic, anti-atherogenic, anti-inflammatory, and insulin-
sensitizing properties that mediate the pathogenesis of metabolic and cardiovascular disease98, 99. 
Leptin, another adipokine, is a hormone predominantly secreted by adipose tissue and has also 
been found in other tissues such as ovaries, placenta, and the brain100, 101. Leptin can moderate 
energy homeostasis through interaction with central circuits in the hypothalamus102. Obese 
children have been shown to have lower circulating adiponectin and higher leptin103. 
 
2.9 Metabolomics 
 Technological advances in omics disciplines have allowed for more in-depth 
characterization of biological samples. For instance, metabolomics has emerged as a useful tool 
to examine the profiles of small molecule metabolites in biospecimens104. Untargeted 
metabolomics measures thousands of metabolites in a biological sample, while targeted methods 
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focuses on a subset of metabolites, generally categorized by their involvement in specific 
biological pathways105. Metabolite levels in humans have been associated with obesity106, age105, 
genetic variants107, and epigenetics108, 109.  
 
2.10 CHAMACOS Cohort 
	
Figure 2.1 Previous and proposed research in the CHAMACOS cohort. Previously 
published or pending works with Gwen Tindula included as a co-author include: 1) Zhou et al. 
2018110, 2) Solomon et al. 2018111, and an 3) upcoming publication on child BMI and newborn 
DNA methylation. 
 
 The CHAMACOS birth cohort is well-suited to study the interplay between early life 
exposure, DNA methylation, and child obesity status. A total of 601 pregnant women were 
enrolled in the CHAMACOS study, and 532 remained in the study at delivery. CHAMACOS 
mothers were primarily young (M=25.6±5.3 years), married, low-income, Mexican-born, 
Spanish-speaking women who were farm workers themselves or lived with farm workers at the 
time of enrollment. Assessments have been conducted at ~13 and 26 weeks gestation, after 
delivery, and when the children were between 6 months and 18 years of age. 
 Mothers and children in CHAMACOS have a high prevalence of obesity. Among 
mothers, 23% have pre-pregnancy BMI’s greater than 30 kg/m2. Previous assessment in the 
CHAMACOS study found strong associations between maternal and child obesity86. 
Specifically, having an obese mother significantly increased the odds of the child being 
overweight or obese (adjusted OR=2.4). Additionally, we examined the relationship between 
pre-pregnancy BMI and maternal metabolomics profiles, observing numerous associations of 
metabolomic markers involved in lipid and nucleic acid metabolism and the inflammatory 
response with maternal BMI110. The influence of maternal depressive symptoms on child obesity 
at age 7 was also examined in CHAMACOS. Children whose mothers consistently demonstrated 
depressive symptoms had 2.4 times the adjusted odds of overweight/obesity compared to those 
whose mothers never experienced symptoms of depression112. In addition, we explored the 
relationship of parental obesity and child growth trajectories with imprinted gene methylation. 
We did not observe any significant associations between parental obesity status and imprinted 
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gene DNA methylation, contrary to previous findings in the NEST cohort40, 97. We observed a 
negative relationship between PEG3 methylation and average childhood adiponectin and a 
positive relationship between PLAGL1 and log leptin levels, which were attenuated after 
adjusting p-values for multiple hypothesis testing.  
 In addition to the parental and child obesity research, we have also examined the effects 
of environmental exposures during pregnancy on newborn DNA methylation. We assessed the 
relationship between genome-wide DNA methylation patterns in 336 CHAMACOS newborns 
using the 450K platform and phthalate exposure at two time points in early and late pregnancy, 
adjusting for cord blood cell composition113. Site-specific analysis uncovered several significant 
CpG sites associated with phthalate metabolite concentrations during pregnancy that remained 
after adjustment for multiple comparisons (FDR). Using the bioinformatics tools DMRcate and 
comb-p to determine DMRs, characterized by multiple adjacent CpG sites with different 
methylation profiles based on phenotype, identified 27 regions that overlapped between the two 
methodologies that were significantly related to multiple phthalate metabolites. Many of the 
DMR hits were located in genes involved in development and metabolic health.  
 
2.11 Significance 
 The first two chapters of this dissertation seek to address the gaps in our understanding of 
the relationship between in utero exposure and DNA methylation of Mexican-American 
newborns. The focus of Chapter 3 is to identify the potential role of phthalate exposure on 
imprinted genes. Phthalates are ubiquitous chemicals with numerous adverse impacts on human 
health. The research described in Chapter 3 is essential to understand how exposure to 
phthalates, known endocrine disrupting chemicals, can affect epigenetic regulation of imprinted 
genes, which are determinants of early childhood growth. Chapter 4 examines how maternal 
lipid metabolites during pregnancy are related to infant genome-wide DNA methylation. 
Epigenetic dysregulation in newborns could be one mechanism to explain previous studies 
identifying links between lipid metabolomic profiles in pregnant women and poor birth 
outcomes. Chapters 3 and 4 will add to the growing evidence of the potential role of in utero 
exposures on DNA methylation. Altered DNA methylation status is posited to mediate observed 
relationships between early life exposures, fetal development, and future health trajectories, a 
concept described by the Developmental Origins of Health and Disease.   
Chapter 5 examines how postnatal home environment can influence obesity risk in 
adolescents. Much of the current research on obesity focuses on how excessive caloric intake and 
a sedentary lifestyle impact obesity status. The research described in this chapter seeks to 
understand the connection of maternal depressive symptoms, perceived social support and home 
learning environment with adipokines and obesity in youth as they age. This research is essential 
since childhood obesity is linked with other co-morbidities and can increase risk of obesity and 
disease in adulthood. Identifying additional contributing risk factors of obesity and potential 
avenues of intervention is critical to address this significant public health issue. 
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CHAPTER 3. DNA Methylation of Imprinted Genes in Mexican-American Newborn 
Children with Prenatal Phthalate Exposure 
 
3.1 Abstract 
Background: Imprinted genes exhibit expression in a parent-of-origin-dependent manner and are 
critical for child development. Recent limited evidence suggests that prenatal exposure to 
phthalates, ubiquitous endocrine disruptors, can affect their epigenetic dysregulation. Methods: 
We quantified DNA methylation of nine imprinted gene differentially methylated regions by 
pyrosequencing in 296 cord blood DNA samples in a Mexican-American cohort. Fetal exposure 
was estimated by phthalate metabolite concentrations in maternal urine samples during 
pregnancy. Results: Several differentially methylated regions of imprinted genes were associated 
with high molecular weight phthalates. The most consistent, positive, and False Discovery Rate 
significant associations were observed for MEG3. Conclusions: Phthalate exposure in utero may 
affect methylation status of imprinted genes in newborn children.  
 
3.2 Introduction 
 Epigenetic influences on gene expression have been implicated as a mediator of the 
relationship between environmental exposures and health status. Early life adverse environments 
can cause epigenetic shifts, establishing disease trajectories into adulthood, an idea described by 
the Developmental Origins of Health and Disease (DOHaD) hypothesis1, 2. Epigenetic 
modifications can alter gene expression without changing the underlying nucleotide sequence. 
DNA methylation is the epigenetic mechanism most often studied1, 3, 4. It is simultaneously 
heritable and susceptible to environmental insults, and is able to reveal cumulative effects of 
environmental exposures throughout the life course5, 6.  
Genomic imprinting involves the expression of only one allele of the gene and is 
dependent on the parental origin of the expressed allele7. The determination of active versus 
inactive allele is regulated by DNA methylation that is established during the process of 
epigenetic reprogramming that occurs in the developing gametes8. The majority of the known 
imprinted genes within the human genome have differentially methylated regions (DMRs) whose 
methylation is also parent-of-origin-dependent9, 10. Methylation patterns in the DMRs are 
remodeled and established prior to germ layer specification, and are maintained in somatic 
tissues throughout life8. A number of human studies have demonstrated the effects of 
environmental exposures on imprinted gene DNA methylation, including the influence of diet11-
14, cigarette smoke15, maternal antibiotic use16, metal exposure17-22, and maternal stress23, 24. 
Differentially methylated regions of imprinted genes represent a unique opportunity to assess the 
effects of in utero exposure since they influence development and growth in early life18. 
 Limited but growing evidence indicates that exposure to phthalates is associated with 
DNA methylation changes of imprinted genes25-27. Phthalates, diesters of phthalic acid, are a 
family of chemicals often found in consumer products, resulting in common exposure in the 
United States28, 29. Some phthalates, such as di-(2-ethylhexyl) phthalate (DEHP), are added to 
plastics to increase flexibility and can be found in toys, plastic containers, and medical supplies. 
Other phthalates, such as diethyl phthalate (DEP), are used as solvents in personal care products 
such as perfumes and lotions30. Common routes of exposure to phthalates, which are not 
chemically bound to their substrates and leach into the environment, include ingestion, dermal 
absorption, and inhalation. Previous studies in humans have demonstrated associations between 
phthalate exposure during or prior to pregnancy and adverse impacts on health outcomes in 
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children, including altered birth weight31-33, gestational age34, 35, pre-term birth36, 37, child growth 
and development38, 39, child behavior40, and asthma41.  
Research in animals42-45 has shown associations between phthalates and global and site-
specific methylation; however, there is a paucity of information on imprinted gene DMR 
methylation in relation to phthalate exposure in utero. Only two human studies are available at 
this time that have examined the relationship between phthalate exposure during pregnancy and 
placental imprinted gene methylation (H19 and IGF2)25, 27. Currently there is no data available 
on the relationship between cord blood imprinted gene methylation profiles and prenatal 
exposure to phthalates.  
Previously, we reported on the prenatal phthalate metabolite concentrations in 
participants of the Center for the Health Assessment of Mothers and Children of Salinas 
(CHAMACOS) study and observed inverse associations of MEP concentrations with DNA 
methylation of repetitive elements in newborns and children46. We have also assessed the 
relationship between prenatal phthalate exposure in CHAMACOS mothers and both genome-
wide site-specific and region DNA methylation as assessed by the 450K array in newborns, 
identifying 27 different regions within the human genome associated primarily with DEHP 
metabolites47. The objective of the present study is to assess the impact of prenatal phthalate 
exposure on DNA methylation of imprinted genes in CHAMACOS newborns. 
 
3.3 Methods 
Study Subjects 
CHAMACOS is a longitudinal birth cohort study assessing neurological, developmental, 
and respiratory health effects of environmental exposure in pregnant Mexican-American women 
and their children residing in the agricultural region of Salinas Valley, CA48. From 1999-2000, a 
total of 601 pregnant women were enrolled in the study and 527 women delivered live, singleton 
newborns. At the time of enrollment, CHAMACOS mothers were at least 18 years of age, 
Spanish or English speaking, eligible for low income health insurance, and were receiving 
prenatal care at one of several participating clinics. During pregnancy, CHAMACOS mothers 
were interviewed twice (13.2 ± 5.1 and 26.0 ± 2.7 weeks gestation) by trained bilingual, 
bicultural staff regarding reproductive and medical history, sociodemographic factors, and 
pregnancy-specific lifestyle and environmental exposures48, 49. The pregnancy visits will 
subsequently be referred to as either the early or late pregnancy visits. 
Immediately following delivery, whole cord blood was collected from the umbilical vein 
in BD vacutainers (Becton, Dickinson and Company, Franklin Lakes, NJ) without anticoagulant. 
Blood specimens were allowed to clot for at least 30 minutes, centrifuged at 1200 rpm for 10 
minutes, divided into serum and blood clot aliquots, and stored at -80°C. The QIAamp Blood 
DNA Maxi kit (Qiagen, Inc., Santa Clarita, CA) was used to isolate genomic DNA from clots as 
previously described50. Methylation of nine imprinted gene DMRs was measured in 296 
newborn children (148 girls and 148 boys) that had sufficient DNA available for analysis. The 
subset was not significantly different from the main CHAMACOS cohort in many demographic 
and exposure characteristics (child sex, poverty index, education, gestational age, and parity). 
However, mothers in this sample tended to be slightly younger and more obese, lived fewer 
years in the United States, and gave birth to children that were less likely to have a low birth 
weight. The number of CHAMACOS participants with pyrosequencing data is approximately 
double the subjects included in existing literature assessing the relationship between phthalate 
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exposure and imprinted genes25, 27 and we anticipate we will have sufficient power to detect a 
minimum of a 0.05 linear correlation between phthalates and imprinted genes. 
CHAMACOS study protocols were approved by the University of California, Berkeley 
Committee for Protection of Human Subjects. All mothers provided written informed consent at 
the time of enrollment.  
 
Phthalate Metabolite Measurements 
 Maternal urine samples were collected during the early and late pregnancy visits. The 
urine samples were aliquoted, barcoded, and stored at -80°C in the UC Berkeley School of 
Public Health Biorepository. Eleven phthalate metabolites were quantified using online solid 
phase extraction coupled with isotope dilution high-performance liquid chromatography-
electrospray ionization-tandem mass spectrometry, as previously described46, 49, 51, 52. The 
metabolites measured included three LMW metabolites (MEP, mono-n-butyl phthalate (MBP), 
mono-isobutyl phthalate (MiBP)), four DEHP metabolites (mono(2-ethylhexyl) phthalate 
(MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) 
phthalate (MEOHP), mono(2-ethyl-5-carboxypentyl) phthalate (MECPP)), and four high 
molecular weight (HMW) metabolites (monobenzyl phthalate (MBzP), mono(3-carboxypropyl) 
phthalate (MCPP), monocarboxyoctyl phthalate (MCOP), monocarboxynonyl phthalate 
(MCNP)). Quality control procedures comprised incorporation of laboratory and field blanks, 
calibration standards, and spiked controls with low and high concentrations into the experimental 
runs.  
The limits of detection (LOD) for all the phthalate metabolites have been previously 
described46, 51, 53. The instrumental reading values were used when the measured phthalate 
metabolite concentrations fell below the LOD. In instances where the measured concentrations 
were below the LOD and instrumental signals were unavailable, the “fill-in” method, described 
in Lubin et al.54 was used to impute phthalate metabolite concentrations from a log-normal 
distribution. Summary measurements of the DEHP metabolites in units of micrograms per liter 
were generated as described previously55. Specifically, molar concentrations of each DEHP 
metabolite were calculated by dividing the concentration of the metabolite by its molecular 
weight. The molar concentrations for each DEHP phthalate metabolite were summed and then 
multiplied by the average molecular weight of the metabolites. All phthalate metabolites, with 
the exception of the DEHP metabolites, were analyzed individually and HMW and LMW sum 
variables were not generated since values are largely driven by DEHP and DEP metabolites, 
respectively. Phthalate metabolite concentrations (micrograms per liter) were divided by 
creatinine concentrations (grams per liter), measured using a commercially available diagnostic 
enzyme method (Vitros CREA slides; Ortho Clinical Diagnostics, Raritan, NJ) concurrently with 
the phthalate metabolites, to generate values (micrograms per gram creatinine) adjusted for 
urinary dilution as previously described49. 
Since we anticipate that average phthalate metabolite concentrations during pregnancy 
will be a more stable indicator of pregnancy exposure, we assessed in utero phthalate exposure 
as the average of the log10 transformed concentrations of creatinine-corrected phthalate 
metabolites from the two prenatal visits52. Participants with measurements greater or less than 
three times the interquartile range for a particular phthalate were removed from analyses. All 
descriptive analyses, figures, and regression models included creatinine adjusted phthalate 
metabolite concentrations averaged across pregnancy. Additionally, we performed a sensitivity 
analysis that included adjusting for urinary dilution using specific gravity instead of creatinine, 
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and we observed that it did not affect the findings. Specific gravity was quantified with a 
refractometer (National Instrument Company, Inc., Baltimore, MD), and urinary phthalate 
metabolites were adjusted for specific gravity as previously described46. The results of the 
principal component and mean methylation analyses of the imprinted gene and average phthalate 
exposure during pregnancy when adjusting for specific gravity were similar to the creatinine 
adjusted models. 
 
DNA Methylation Analyses 
 The EZ DNA Methylation kit (Zymo Research, Irvine, CA, USA) was used for bisulfite 
conversion of 800 ng of DNA, following the manufacturer’s instructions. Treating DNA with 
sodium bisulfite converts unmethylated cytosines to uracils and leaves methylated cytosines 
unchanged.  
The PyroMark PCR Kit (Qiagen, Valencia, CA, USA) was used to prepare bisulfite-
treated DNA for PCR amplification, using published primer sequences for nine imprinted gene 
DMRs and assays previously developed and validated at Duke University8, 56. These imprinted 
genes were selected based on their biological significance and availability of reliable assays25, 57-
61. Pyrosequencing of the amplified and bisulfite converted DNA was achieved using the 
Pyromark Q96 MD system (Qiagen), yielding percent methylation estimates for the CpG sites 
within the sequence analyzed for each DMR. Methylation was measured for the following 
imprinted genes: H19, Insulin-like Growth Factor 2 (IGF2), Maternally Expressed Gene 3 
(MEG3 and MEG3-IG), Mesoderm Specific Transcript (MEST), Neuronatin (NNAT), 
Pleomorphic Adenoma Gene-Like 1 (PLAGL1), Paternally Expressed Gene 3 (PEG3), and 
Epsilon Sarcoglycan/ Paternally Expressed Gene 10 (SGCE/PEG10). Specifically, methylation 
was measured at the DMRs upstream of IGF2 exon 3 (chr 11p15.5; 3 CpG sites), upstream of the 
H19 gene (chr 11p15.5; 4 CpG sites), two DMRs involved in regulating the DLK1/MEG3 
imprinted domain (chr 14q32.2; MEG3-IG: 4 CpG sites; MEG3: 7 CpG sites), the MEST 
promoter (chr 7q32.2; 4 CpG sites), the NNAT locus (chr 20q11.23; 3 CpG sites), the PEG3 
promoter (chr 19q13.43; 10 CpG sites), the PLAGL1 locus (chr 6q24.2; 6 CpG sites), and the 
SGCE/PEG10 promoter (chr 7q21.3; 6 CpG sites). The paternal allele is expressed for the genes 
IGF2, DLK1, MEST, NNAT, PEG3, PLAGL1, and SGCE; whereas the maternal allele is 
expressed in MEG3 and H19. The selected imprinted genes are critical in the regulation of early 
growth61, and alterations of DNA methylation by environmental insults, such as phthalate 
exposure, could have implications for imprinted gene expression and downstream effects on 
growth trajectories. In the CHAMACOS cohort, we have observed that in utero exposure to 
MEP is associated with increased odds of being overweight or obese that persists from age 5 to 
1252. Quality assurance measures involved inclusion of technical repeats and positive and 
negative controls. Samples whose methylation values exceeded two standard deviations from the 
mean for the plate were reanalyzed. The coefficients of variation (CV) of intra-plate repeat 
measures ranged from 1-3%. Using mixtures of DNA with fully methylated and unmethylated 
sequences8, 61, we have previously shown that pyrosequencing allows for the detection of 0.5-5% 
methylation differences. 
Three approaches were used to account for cell composition in the analysis based on 
cytological differential cell counts62 and 450K-array estimates47. The methods included adjusting 
for 1) cytological differential cell counts (DCC) in a subset of cord blood samples46, 62 and 2) 
estimating cell type proportions from CHAMACOS 450K cord blood DNA methylation data47 
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using adult63 and cord blood64 flow sorted reference panels. The cord blood reference panel 
includes estimates of nucleated red blood cells (nRBCs). 
 
Gene Expression Analysis 
Validation of significant hits of the relationship between average phthalate metabolites 
during pregnancy and imprinted gene methylation in newborns was performed using a two-step 
RT-PCR in a subset of the CHAMACOS participants with imprinted gene data and available 
isolated RNA. Specifically, we assessed the overall expression of MEG3 in 119 CHAMACOS 
children with imprinted gene data, since methylation changes due to environment exposure could 
lead to alteration of gene expression. As a negative control, we also examined overall expression 
patterns in DLK1 and its relationship with MEG3-IG methylation, an imprinted gene DMR 
where we did not expect to see changes in gene expression since the mean methylation across the 
DMR was not significantly associated with phthalate exposure. Expression of the reference gene 
GAPDH was used as a control. SuperScript™ IV VILO™ Master Mix was used to convert RNA 
to cDNA. Predesigned TaqMan Gene Primer Assays for MEG3, MEG3-IG, and GAPDH, as well 
as, TaqMan Fast Advanced Master Mix were used in the RT-PCR analysis according to the 
manufacturer’s protocols. Reactions were performed on a Rotor-Gene 6000 (Qiagen, formerly 
Corbett Life Science). Amplicon specificity was verified by reviewing melt curves. Ct values 
were calculated for each gene, and ΔCt values, calculated as the difference between the 
imprinted genes (MEG3 or MEG3-IG) and GAPDH Ct values, were used in statistical analysis. 
Interplate replicates and negative and positive controls were included in the expression analysis 
for quality control.  
 
Statistical Analyses 
  Covariates included in the regression models were selected from factors related to 
phthalate metabolite levels in the CHAMACOS cohort, after performing bivariate analyses (i.e. 
linear regressions, Student’s T-test, ANOVA), and important covariates identified in previous 
studies examining the relationship between imprinted genes and prenatal phthalate exposure. The 
relevant covariates include pre-pregnancy BMI, years in the US, parity, and child sex. Pre-
pregnancy BMI and years in the US were coded as continuous variables, while parity and sex 
were coded as shown in Table 3.1. Additionally, a plate (batch) variable was included in the 
regression models to adjust for technical effects.  
 Prior to performing regression analyses, we logit-transformed the methylation fractions to 
'M-values' to reduce dependence of their variance on their mean levels. Methylation fractions 
have more intuitive biological interpretation, but the M-value is more statistically valid for the 
differential analysis of methylation levels65, 66. Methylation outliers, specifically M-values that 
were below the 25th percentile minus 3 times the interquartile range and values greater than the 
75th percentile plus 3 times the interquartile range, were designated as not available (NA) in the 
data set, resulting in one to four substitutions for all imprinted genes, with the exception of the 
MEST and PLAGL1 DMRs. As a result of the correlation between CpG sites within a DMR, we 
decided to conduct DMR-level principal components (PCs) analyses of the data to determine the 
independent M-value methylation signals, represented as linear combinations of CpGs that 
explain at least 95% of variability at the locus. DMR-level principal components (PC) analyses 
yielded a total of 26 PCs across the nine investigated imprinted gene DMRs (number of PCs: 
H19=2, IGF2=2, MEG3=1, MEG3-IG=3, MEST=2, NNAT=2, PLAGL1=4, PEG3=6, and 
SGCE/PEG10=4). The first PCs for all imprinted gene DMRs demonstrated similar contributions 
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for each CpG to the variance explained by PC1. We fit separate regression models for each 
combination of the 26 PCs and 12 phthalate metabolite variables (11 phthalate metabolites and 
the DEHP summary variable) averaged across pregnancy, with the PCs as the response and the 
average phthalate metabolite concentrations and confounder variables (mentioned above) as 
covariates. Since the analysis with the PCs does not provide information regarding direction of 
association, we also performed separate regression analyses for each imprinted gene DMR using 
the average M-value methylation across the CpGs within the DMR as the outcome. We 
confirmed regression findings of the relationship between average phthalate metabolites and 
mean imprinted gene methylation by implementing a bootstrap analysis, sampling individuals 
with replacement for 1,000 iterations.  
 Since many imprinted genes impact early growth patterns and MEG3 has been associated 
previously with growth outcomes at birth, we performed additional analyses to examine the 
relationship between average methylation of the MEG3 DMR and birth weight. A dichotomous 
birth weight variable was generated at a cutoff of 2,500 grams to distinguish between low and 
normal/high birth weight newborns. We performed a two sample t-test to compare mean 
methylation values in the MEG3 DMR in the two birth weight groups. We also ran regressions to 
test the association between MEG3 mean methylation and birth weight, coded as a continuous or 
binary variable, adjusting for infant sex, maternal pre-pregnancy BMI, methylation plate, route 
of delivery, and gestational age. 
We controlled for the false discovery rate (FDR). The FDR can be defined as the average 
number of false rejections of the null hypothesis divided by the total number of rejections67. All 
statistical analyses were performed in R Version 3.2.3 (R Foundation for Statistical Computing, 
Vienna, Austria, 2013). P-values less than 0.05 were considered significant, and two-sided 
statistical tests were used. 
 
3.4 Results 
CHAMACOS Participants 
 Demographic characteristics of CHAMACOS mothers and children are presented in 
Table 3.1. Most mothers were young, living below the poverty level, had previously delivered 
children, had low levels of education, and were overweight or obese (BMI ≥ 25 kg/m2) prior to 
pregnancy. Approximately half of the women resided in the US for over 5 years at the time of 
delivery (mean = 6.9 years, SD = 6.9 years). The majority of the children, equally represented by 
boys and girls, were born term (93.2%) and with a normal birth weight (96.6%). 
 
Phthalate Exposure 
 Table 3.2 shows the distributions of average phthalate metabolite concentrations across 
pregnancy for the CHAMACOS mothers included in this study. Detection frequencies of 
phthalate metabolites during pregnancy were 90-100%. Compared to ten other phthalate 
metabolites, MEP had the highest urinary concentrations during pregnancy (IQR: 90.7-444.7 
µg/g creatinine) in the CHAMACOS cohort49, 52, consistent with trends observed in the general 
U.S. population of adults28. Levels of urinary MEHHP (IQR: 9.5-29.2), MEOHP (IQR: 7.0-
20.7), and MECPP (IQR: 17.7-45.3) contributed most to the DEHP sum concentration. 
 
DNA Methylation of Imprinted Genes 
 Distributions of DNA methylation values at individual CpG sites within each DMR and 
average methylation for each of the nine imprinted gene DMRs are shown in Figure 3.1. The 
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percentage of DNA methylation varies between imprinted genes and within the individual CpG 
sites within DMRs. MEG3 exhibited the highest (73±5%) and PEG3 had the lowest (35±1%) 
average methylation compared to the other seven imprinted genes DMRs, which were closer to 
the expected methylation level of 50% and ranged from 44 to 55%. Moreover, whereas some of 
the imprinted genes (H19, MEST, PLAGL1, SGCE) have relatively similar CpG methylation 
values across each DMR, the MEG3-IG and NNAT DMRs demonstrate a wide range of 
methylation in CpGs from different individuals (MEG3-IG: 36-71%; NNAT: 42-75%).  
 
Phthalates and DMR Methylation Principal Component Analyses  
 Significant results of the regression analyses of associations between PCs of imprinted 
gene DMR methylation in cord blood DNA and phthalate metabolite concentrations during 
pregnancy are shown in Table 3.3. After adjusting for years in the United States at the time of 
pregnancy, parity, pre-pregnancy BMI, child sex, and batch, HMW phthalate metabolites were 
related to PCs of the MEG3 DMRs and PC 3 of PEG3. All DEHP metabolites assessed were 
significantly associated with PC1 of the MEG3 DMR (MEHP: p=0.03; MEHHP: p=0.002; 
MEOHP: p=0.0003; MECPP: p=0.0001). MBzP was also related to PC1 of the MEG3 DMR 
(p=0.01). MCPP was associated with PC2 of the MEG3-IG DMR (p=0.01). Average pregnancy 
levels of MCOP (p=0.02) and MCNP (p=0.03) were associated with the third principal 
component of PEG3. Of the observed associations between the average phthalate metabolites 
during pregnancy and the MEG3 DMRs, only the associations between MEG3 and certain DEHP 
metabolites (MEOHP, MECPP, Σ DEHP) remained significant after FDR adjustment (all 
p<0.04). 
 
Phthalates and Imprinted Gene Average DMR Methylation 
In order to determine directions of association, we analyzed the relationship between 
phthalate exposure and DNA methylation averaged across all CpG sites within each imprinted 
gene DMR (Figure 3.2, Table 3.4). In crude models without adjustment for confounders, we 
found a positive association between average pregnancy DEHP metabolites and mean 
methylation percent at the MEG3 DMR (Figure 3.2, all p<0.05). In models adjusting for 
covariates, MEG3-IG and PEG3, which were significantly associated with some of the phthalate 
metabolites in the PC analysis, were no longer significant in the analysis with mean M-value 
methylation as the outcome (MEG3-IG and MCPP; PEG3 and MCOP; PEG3 and MCNP; all p-
values>0.05). MBzP (β=0.17, p=0.01) and DEHP metabolites (MEHP: β=0.12, p=0.03; 
MEHHP: β=0.21, p=0.002; MEOHP: β=0.23, p=0.0003; MECPP: β=0.31, p=0.00007) were 
positively associated with mean methylation across the MEG3 DMR. All of the observed 
relationships remained significant after FDR adjustment (all p<0.05), with the exception of the 
associations with MEHP and MBzP. Bootstrap analysis confirmed the findings; specifically, the 
significant and positive association between HMW phthalates and mean methylation across CpG 
sites within the MEG3 DMR.  
 
Adjustment for Cell Composition 
Figure 3.3 presents the regression estimates for the significant relationships of the mean 
MEG3 methylation and prenatal phthalate metabolite concentrations adjusting for cell type 
composition using three different methodologies as described in the methods section. The array-
based estimates of cell composition47, 64 produced estimates of the regression coefficients similar 
to the model without cell type adjustment (unadjusted). Coefficients from models adjusting for 
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cytological DCC62 showed even stronger relationships between phthalate exposure and MEG3 
methylation in the same direction. Adjusting for white blood cell composition estimates using 
CHAMACOS 450K array data and the cord blood flow sorted reference panel replicated the 
crude models of the imprinted gene mean methylation and average pregnancy phthalate 
metabolites, suggesting limited bias due to cell type composition.  
 
Gene Expression Validation 
Following identification of significant hits for the association between DEHP and BzBP 
phthalate metabolites and MEG3 methylation, we assessed gene expression of the MEG3 gene in 
a subset of 119 CHAMACOS participants. Ct values for MEG3 ranged from 22 to 36, with a 
mean of 27.6. As expected based on previous relationships between methylation and expression6, 
MEG3 M-value methylation was inversely correlated with MEG3 expression relative to the 
housekeeping gene GAPDH (Pearson r=-0.10, p=0.29). As a control, we also assessed the 
relationship between DLK1 expression and MEG3-IG mean methylation, an imprinted gene 
DMR that was not significantly associated with phthalate exposure. As expected, we did not 
observe a significant relationship (Pearson r=-0.05, p=0.58). Additionally, we tested the 
relationships between phthalate metabolite concentrations and MEG3 expression, adjusting for 
the covariates identified in the methylation analysis. We observed consistent negative 
associations between DEHP metabolites and MEG3 expression (MEHP: β=-0.44, MEHHP: β=   
-1.14, MEOHP: β=-0.63, MECPP: β=-1.21); however, none of the associations reached 
statistical significance.  
 
Imprinted Gene Methylation and Birth Weight 
 We found a significant difference in mean MEG3 percent methylation levels comparing 
low birth weight newborns and newborns with normal to high birth weights (t=-2.35, p=0.04), 
with lower average methylation values in the low birth weight group. However, the regression 
analyses did not show a significant relationship between MEG3 methylation and continuous and 
binary birth weight in the CHAMACOS newborns. 
 
3.5 Discussion 
 We examined the association of prenatal phthalate exposure and imprinted gene 
methylation profiles in newborn children using DNA isolated from cord blood. Previous analysis 
in the CHAMACOS cohort of repetitive element methylation and array-based DMRs uncovered 
significant associations of DNA methylation in cord blood with MEP and DEHP metabolites, 
respectively46, 47. In the current study of nine imprinted genes, the most consistent findings were 
the associations between DEHP and BzBP phthalate metabolites and DNA methylation of the 
MEG3 DMR, located within an intron, downstream of the MEG3 promoter68. DNA methylation 
profiles in the CHAMACOS cohort were similar to values reported for imprinted genes in other 
cohorts with DNA isolated from cord blood samples68.  
To the best of our knowledge, our study is the first to demonstrate the relationship 
between MEG3 DNA methylation and prenatal phthalate exposure. In CHAMACOS newborns, 
prenatal exposure to several DEHP metabolites was positively and significantly associated with 
DNA methylation at the MEG3 DMR. Validation analysis demonstrated an inverse relationship 
between MEG3 methylation and expression, which is consistent with expected effects of 
hypermethylation. However, this result did not quite reach statistical significance. Relatively 
weak relationships between differential DNA methylation and expression of the same genes is 
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common, as regulatory mechanisms may also include non-coding RNAs and chromatin 
modifications1.   
Hypomethylation or increased expression of MEG3 in humans have previously been 
associated with higher birth weight and large for gestational age status, respectively69, 70. 
Conversely, decreased expression of MEG3 has been observed in human Intrauterine Growth 
Restriction placenta samples71. In the current study, we did not find a significant relationship 
between MEG3 methylation and continuous birth weight, which corroborates a previous report 
by Vidal et al. (2013)16. However, we did observe a significant difference when we contrasted 
MEG3 methylation in low birth weight newborns and normal weight ones. In addition to its 
relationship with birth outcomes, hypermethylation of the MEG3 gene in human tumor samples 
and cell lines has previously been associated with tumorigenesis57, 58, 72-76. Additionally, 
epigenetic and genetic studies have also uncovered links between MEG3 variants and 
methylation patterns and diabetes77. Specifically, Kameswaram et al.78 found decreased 
expression of MEG3 in human islets from T2D organ donors, which was highly correlated with 
hypermethylation of MEG3. Studies in mice have demonstrated that decreased expression of the 
Meg3 gene can impact glucose tolerance and reduce insulin secretion79. Modification of 
epigenetic profiles in MEG3 following environmental exposure could lead to shifts in hormonal 
and metabolic markers, as well as early growth.  
Only two studies have assessed the relationship between pregnancy phthalate exposure 
and imprinted gene methylation, both in placenta samples. Zhao et al.27 measured urinary 
phthalate concentrations of 5 metabolites (2 LMW and 3 HMW) and DNA methylation of IGF2 
(2 CpGs) in 181 placenta samples collected in China. The researchers observed that DEHP 
metabolites were significantly and negatively associated with IGF2 DNA methylation. 
Additionally, LaRocca et al.25 examined the association between phthalate metabolite 
concentrations and DNA methylation of the H19 and IGF2 imprinted genes in 179 placenta 
samples from two cohorts, the Harvard Epigenetic Birth Cohort (HEBC) and the Predictors of 
Preeclampsia Study (POPS). The authors found a significant inverse relationship between H19 
methylation in placenta and the sum of the LMW phthalates metabolite concentrations and the 
sum of all the 11 phthalate metabolites measured. A similar pattern was observed for the IGF2 
DMR0. They also observed an inverse association between DEHP metabolites and IGF2 DMR0, 
similar to the results seen in the study by Zhao et al. However, both of these studies did not 
analyze MEG3 methylation in respect to phthalates. 
The number of CpG sites in the studies assessing placenta DNA methylation and the cord 
blood analysis in CHAMACOS differ between the studies. Additionally, only two imprinted 
genes were assessed in the placenta studies, while our study involved eight imprinted genes with 
nine DMRs. We are also mindful that the difference between the tissues used (placenta vs. cord 
blood) may also be the reason for observed differences in methylation results with phthalate 
exposure.  
A recent study by Goodrich et al.26 examined the relationship between prenatal and 
childhood exposure to heavy metals and endocrine disrupting chemicals, including phthalates, 
and DNA methylation of differentially methylated regions of two imprinted genes (H19: 4 CpG 
sites, IGF2: 7 CpG sites) in peri-adolescents. They found that phthalate metabolite levels (MBzP 
and MIBP) in maternal urine samples were associated with H19 hypermethylation in blood from 
247 8-14 year old children, but this finding was attenuated to non-significance after adjustment 
for multiple testing. Overall, the CHAMACOS results as well as the findings by LaRocca et 
al.25, Zhao et al.27, and Goodrich et al.26 suggest potential epigenetic modifications in imprinted 
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genes involved in fetal growth, in association with prenatal phthalate exposure from the time of 
birth that may persist into adolescence. 
A hypothesized mechanism by which exposure to environmental chemicals may induce 
epigenetic shifts involves altered transcription factor occupancy. Martin and Fry80 performed an 
analysis across 11 studies that included altered cord blood and placental methylation patterns of 
CpG sites within 341 genes related to five environmental contaminants (lead, arsenic, cadmium, 
tobacco smoke, and mercury). They found that 56 transcription factor binding sites were 
enriched in the promoter regions of the genes, which could impact the access of DNA 
methyltransferase to CpG sites, inhibiting the process of DNA methylation and leading to 
hypomethylation of the gene. Additionally, the authors provided suggestive evidence that 
glucocorticoid-receptor dependent signaling may mediate the relationship between 
environmental chemical exposure and transcription factor activity, since the promoter regions of 
38 of the 56 genes encoding the transcription factors contained glucocorticoid-responsive-related 
sequence elements. It is possible that prenatal exposure to phthalates could initiate a similar 
response of altered transcription factor activity in the current study in the MEG3 DMR, located 
downstream of the promoter region, resulting in methylation shifts. Future studies should further 
explore the mechanism proposed by Martin and Fry in additional environmental contaminants, 
including phthalates. 
One of the notable strengths of our study involves the novel investigation of DNA 
methylation profiles of multiple imprinted genes in newborns in relation to prenatal phthalates, a 
ubiquitous endocrine disruptor. Two previous studies25, 27 assessed the role of pregnancy 
phthalate levels on DNA methylation in imprinted genes; however, they used placenta samples 
and only for three or fewer imprinted regions. In addition to the advantages of assessing a greater 
number of imprinted genes in our study, our analyses also benefited from a larger sample size.  
 There were also several limitations in our study. In the umbilical cord, nRBCs and 
leukocytes mixed in the clots may contribute to DNA methylation levels64. However, we were 
able to account for variable leukocyte composition typical in umbilical cord blood in sensitivity 
analyses using cytological differential cell count62, as well as a cord blood reference panel 
including nRBCs47, 64. The results for the models that did and did not adjust for cell counts were 
very similar. Another potential limitation involves the applicability of the findings to other 
populations, given that the CHAMACOS participants are Mexican-Americans from families 
with low socioeconomic status. Since observed exposure levels to phthalates in CHAMACOS 
women were similar to the general population of U.S. adults, the data are likely relevant to many 
other populations. In this study, we have focused on nine imprinted gene DMRs that have been 
previously established and validated, and we intend to explore other regions with parental-origin-
dependent differential methylation in the future. 
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3.8 Tables 
Table 3.1 Demographic characteristics of CHAMACOS mothers and children (1999-2000) 
aTotal number of observations for maternal pre-pregnancy BMI varies due to missing data 
Abbreviations: BMI, body mass index; CHAMACOS, Center for the Health Assessment of 
Mothers and Children of Salinas; DMR, differentially methylated region 
Characteristic 
CHAMACOS mothers and their 
children with imprinted gene DMR 
methylation data (N=296) n (%) 
Child sex   
Boy 148 (50.0) 
Girl 148 (50.0) 
    Child gestational age at birth   
34-36 weeks 20 (6.8) 
≥ 37 weeks 276 (93.2) 
    Child birthweight   
Low birthweight (< 2500 g) 10 (3.4) 
Normal birthweight (≥ 2500 g) 286 (96.6) 
    
Maternal age at pregnancy   
18-24 137 (46.3) 
25-29 101 (34.1) 
30-34 46 (15.5) 
35-45 12 (4.1) 
    Number of years mother lived in US at pregnancy   
Less than 1 year 55 (18.6) 
1-5 years 102 (34.5) 
6-10 years 70 (23.6) 
11 or more years 69 (23.3) 
    Maternal pre-pregnancy BMIa   
Underweight (< 18.5 kg/m2) 2 (0.7) 
Normal (18.5-24.9 kg/m2) 118 (40.7) 
Overweight (25-29.9 kg/m2) 115 (39.7) 
Obese (≥ 30 kg/m2) 55 (19.0) 
    Parity   
0 106 (35.8) 
≥ 1 190 (64.2) 
    Education   
≤ 6th grade 125 (42.2) 
7-12th grade 114 (38.5) 
≥ High school graduate 57 (19.3) 
    Poverty Status   
≤ Poverty level 184 (62.2) 
> Poverty level 112 (37.8) 
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Table 3.2 Distribution of phthalate metabolite concentrations averaged across pregnancy 
Phthalate 
Metabolite 
Pregnancy Average (N=265) 
Median IQR Minimum Maximum 
MEP 214.2 (90.7, 444.7) 7.2 6607.7 
MBP 24.4 (14.2, 45.3) 3.2 228.6 
MiBP 2.7 (1.6, 5.3) 0.1 192.0 
          
MEHP 3.9 (2.2, 7.0) 0.1 101.6 
MEHHP 16.1 (9.5, 29.2) 1.4 478.6 
MEOHP 12.1 (7.0, 20.7) 0.9 353.4 
MECPP 26.7 (17.7, 45.3) 5.3 665.2 
ΣDEHP 60.9 (37.1, 98.5) 8.0 1524.5 
          
MBzP 8.2 (4.7, 13.8) 0.5 97.4 
MCPP 2.0 (1.3, 2.9) 0.1 28.3 
MCOP 3.4 (2.1, 4.7) 0.5 82.7 
MCNP 1.9 (1.3, 2.6) 0.3 17.1 
All units are in µg/g creatinine.  
Abbreviations: IQR, interquartile range; MEP, monoethyl phthalate; MBP, mono-n-butyl 
phthalate; MiBP, mono-isobutyl phthalate; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, 
mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; 
MECPP, mono(2-ethyl-5-carboxypentyl) phthalate; DEHP, di-2-ethylhexyl phthalate; MBzP, 
monobenzyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; MCOP, monocarboxyoctyl 
phthalate; MCNP, monocarboxynonyl phthalate.  
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Table 3.3 Regression models of average maternal phthalate metabolite concentrations during 
pregnancy with principal components (PCs) of child imprinted gene DMR M-value methylation 
at delivery 
Imprinted Gene DMR PC # Significant Exposure βa 95% CI P-Value 
MEG3 PC 1 MEHP -0.321 (-0.602, -0.039) 0.03 
  PC 1 MEHHP -0.544 (-0.885, -0.203) 2E-03 
  PC 1 MEOHP -0.615 (-0.944, -0.286) 3E-04* 
  PC 1 MECPP -0.812 (-1.211, -0.412) 9E-05* 
  PC 1 Σ DEHP -0.719 (-1.099, -0.338) 3E-04* 
  PC 1 MBzP -0.448 (-0.765, -0.132) 0.01 
MEG3-IG PC 2 MCPP 0.050 (0.013, 0.087) 0.01 
PEG3 PC 3 MCOP -0.051 (-0.095, -0.007) 0.02 
 
PC 3 MCNP -0.055 (-0.104, -0.006) 0.03 
Covariates in each regression model included batch, years in the USA, parity, pre-pregnancy 
BMI, and child sex. Models included log10 transformed concentrations of creatinine-corrected 
phthalate metabolites. 
aβ for PCs are not interpretable; for direction of association, refer to mean methylation analysis 
*Significant after FDR adjustment (all p<0.04). p<0.05 statistically significant. 
Abbreviations: PC, principal component; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, 
mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; 
MECPP, mono(2-ethyl-5-carboxypentyl) phthalate; DEHP, di-2-ethylhexyl phthalate; MBzP, 
monobenzyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; MCOP, monocarboxyoctyl 
phthalate; MCNP, monocarboxynonyl phthalate.  
 
 
Table 3.4 Regression models of average maternal phthalate metabolite concentrations during 
pregnancy with mean child imprinted gene DMR M-value methylation at delivery 
Imprinted Gene DMR Significant Exposure β 95% CI P-Value 
MEG3 MEHP 0.120 (0.015, 0.225) 0.03 
  MEHHP 0.206 (0.078, 0.333) 2E-03* 
  MEOHP 0.232 (0.110, 0.335) 3E-04* 
  MECPP 0.306 (0.157, 0.455) 7E-05* 
  Σ DEHP 0.271 (0.130, 0.413) 2E-04* 
  MBzP 0.168 (0.050, 0.286) 0.01 
Covariates in each regression model included batch, years in the USA, parity, pre-pregnancy 
BMI, and child sex. Models included log10 transformed concentrations of creatinine-corrected 
phthalate metabolites. 
*Significant after FDR adjustment (all p<0.05). p<0.05 statistically significant. 
Abbreviations: FDR, false discovery rate; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, 
mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; 
MECPP, mono(2-ethyl-5-carboxypentyl) phthalate; DEHP, di-2-ethylhexyl phthalate; MBzP, 
monobenzyl phthalate.  
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Figure 3.2 Scatter plots of the crude relationships between prenatal DEHP phthalate metabolites 
and mean percent methylation of the MEG3 differentially methylated region.  
MEHP, mono(2-ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; 
MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) 
phthalate. 
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Figure 3.3 Regression coefficients of the relationships between prenatal DEHP phthalate 
metabolites and mean methylation of the MEG3 DMR with and without cell type adjustment. 
The methods included adjusting for cytological differential cell counts in a subset of cord blood 
samples (Yousefi 2015) and estimating cell type proportions from CHAMACOS 450K cord 
blood DNA methylation data using adult (Solomon 2017) and cord blood (Bakulski 2016) flow 
sorted reference panels. The cord blood reference panel includes estimates of nucleated red blood 
cells (nRBCs). 
*Not statistically significant at p<0.05; all other presented relationships were significant at 
p<0.05. 
MEHP, mono(2-ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; 
MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) 
phthalate; MBzP, monobenzyl phthalate. 
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CHAPTER 4. Pregnancy Lipidomic Profiles and DNA Methylation in Newborns from the 
CHAMACOS Cohort 
 
4.1 Abstract 
Background: Lipids play a role in many biological functions and the newly emerging field of 
lipidomics aims to characterize the varying classes of lipid molecules present in biological 
specimens. Animal models have shown associations between maternal dietary supplementation 
with fatty acids during pregnancy and epigenetic changes in their offspring, demonstrating a 
mechanism through which prenatal environment can affect outcomes in children; however, data 
on maternal lipid metabolite levels during pregnancy and newborn DNA methylation in humans 
are sparse. Methods: In this study, we assessed the relationship of maternal lipid metabolites 
measured in the blood from pregnant women with newborn DNA methylation profiles in the 
CHAMACOS cohort. Targeted metabolomics was performed by selected reaction monitoring 
liquid chromatography and triple quadrupole mass spectrometry to measure 92 metabolites in 
plasma samples of pregnant women at approximately 26 weeks gestation. DNA methylation was 
assessed using the Infinium HumanMethylation 450K BeadChip adjusting for cord blood cell 
composition. Results: We uncovered numerous false discovery rate (FDR) significant 
associations between maternal metabolite levels, particularly phospholipid and lysolipid 
metabolites, and newborn methylation. The majority of the observed relationships were negative, 
suggesting that higher lipid metabolites during pregnancy are associated with lower methylation 
levels at genes related to fetal development. Conclusion: These results further elucidate the 
complex relationship between early life exposures, maternal lipid metabolites, and infant 
epigenetic status. 
 
4.2 Introduction 
 Metabolomics has emerged as a useful tool to examine the profiles of small molecule 
metabolites in biospecimens1. Factors that have been associated with metabolite levels include 
age2, diseases such as obesity3, genetic variants throughout the human genome4, and epigenetics5, 
6. Both untargeted and targeted methodologies are commonly used in metabolomic research, with 
the former measuring thousands of metabolites in a biological sample and the latter focusing on a 
subset of metabolites, often involved in specific biological pathways2. For instance, lipidomics 
evaluates the function and distribution of lipids, which have a greater diversity of molecular 
species compared to the other classes of biological molecules in the body, such as carbohydrates 
and amino acids7.   
 Epigenetic mechanisms regulate gene expression without changes in DNA sequence and 
include DNA methylation, histone modifications, and non-coding RNAs8. DNA methylation is 
the most commonly examined epigenetic mechanism and refers to the addition of a methyl group 
to the C5 position of the cytosine ring in a CpG dinucleotide by DNA methyltransferases9. DNA 
methylation patterns are retained following somatic cell division10. In the CHAMACOS cohort 
and as part of the Pregnancy and Childhood Epigenetics (PACE) consortium, we have explored 
the relationship of infant DNA methylation with early life environmental exposure of mothers to 
chemicals during pregnancy, including endocrine disrupting chemicals11-13 and smoking14. Since 
the epigenome undergoes remodeling and rapid cell division in the prenatal period8, this life 
stage is considered particularly sensitive to environmental insults and can have implications for 
disease trajectories15.  
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There remains a paucity of information on the relationship between metabolite profiles, 
in general and specific to the lipid species, and DNA methylation, particularly the link between 
maternal lipid metabolites during pregnancy and offspring epigenetics, which could be a 
mechanism through which the in utero environment exerts an effect on epigenetic mechanisms 
that could impact offspring health. Most of the existing research on this topic has been conducted 
in animal models and has focused on the relationship between maternal nutrition, including 
dietary supplementation with fatty acids, and offspring methylation status16, 17. Only one study to 
date has examined the association between in utero metabolic traits, including lipid metabolites, 
and DNA methylation profiles in newborns5. The authors found significant relationships between 
maternal fatty acid levels and newborn methylation globally and at target genes related to early 
growth.  
Previous research in the Center for the Health Assessment of Mothers and Children of 
Salinas (CHAMACOS) cohort examined the association between maternal prenatal phthalate 
urine metabolite levels and targeted metabolomic compounds present in plasma and urine, 
collected at 26 weeks gestation18. Additionally, we assessed the relationship between pre-
pregnancy body mass index (BMI) and maternal metabolomics profiles. We observed numerous 
associations of metabolomic markers involved in lipid and nucleic acid metabolism and the 
inflammatory response with both urinary phthalate metabolites and maternal BMI. The current 
study aims to determine the association between maternal metabolomic profiles in pregnancy and 
child DNA methylation at birth, emphasizing metabolites enriched for lipid pathways that were 
confirmed as relevant in previous work in CHAMACOS18. This study will contribute to the 
growing body of evidence of the influence of the early life environment on epigenetic 
mechanisms. 
 
4.3 Methods 
Study population 
Study participants included women and children from the CHAMACOS study, a 
longitudinal birth cohort originally aimed at examining the relationship of pesticide and 
environmental chemical exposure with the health and development of Mexican-American 
children from Salinas Valley, CA. A more in depth discussion of the study population has been 
characterized previously19. From 1999-2000, a total of 601 pregnant women were enrolled, 
resulting in the delivery of 527 liveborn singletons. Two pregnancy interviews were conducted at 
an average of 13.4 and 26.0 weeks gestation, with an additional visit after delivery. This study 
includes the 81 mother–child pairs with both metabolomic data from blood collected at the 
second pregnancy visit and with newborn Illumina HumanMethlyation 450K BeadChip data. 
The University of California, Berkeley Committee for Protection of Human Subjects approved 
all study protocols and written informed consent was obtained from the CHAMACOS mothers.  
 
Pregnancy Metabolite Measurements 
 Biological samples collected from 115 CHAMACOS women around 26 weeks gestation 
(mean=26.4, SD=3.2) were analyzed to characterize maternal metabolomics profiles during 
pregnancy. Detailed descriptions of the metabolomics analyses in the CHAMACOS cohort have 
been previously described18. Briefly, blood from the women was analyzed in duplicates by 
selected reaction monitoring (SRM) liquid chromatography (LC) and triple quadrupole mass 
spectrometry (MS), a method previously validated by the Nomura research group20. SRM was 
used to identify metabolites, which were measured using the area under the curve. C12 MAGE, 
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Pentadecanoic acid, and D3N15 Serine were utilized in the normalization of plasma nonpolar 
positive, plasma nonpolar negative, and plasma polar metabolites, respectively. Laboratory and 
field blanks, as well as internal standards, were included to ensure quality, and repeat samples 
had good reproducibility (CVs ≤ 3–15%). For this study, we focused on the plasma metabolites 
involved in lipid pathways since lipids are involved in diverse biological activities including 
metabolic and structural functions, inflammation, signaling, and endocrine regulation21. 
 
Cord blood collection and processing 
At delivery, hospital staff collected cord blood in two types of vacutainers, one coated in 
heparin (green top) and the other without the anticoagulant (red top). Blood clots were aliquoted 
from the nonheparinized vacutainers and were stored at −80 °C until use in DNA isolation. 
 
DNA preparation 
DNA isolation of anticoagulant-free umbilical cord blood clot samples was performed 
using QIAamp DNA Blood Maxi Kits (Qiagen, Valencia, CA) following the manufacturer’s 
protocol, with the exception of small modifications that were previously described22.  
 
450K BeadChip DNA methylation analysis 
DNA samples of 1ug were bisulfite converted using Zymo Bisulfite Conversion Kits 
(Zymo Research, Irvine, CA), whole genome amplified, enzymatically fragmented, purified, and 
applied to Illumina Infinium HumanMethylation450 BeadChips (Illumina, San Diego, CA) 
following the manufacturer’s instructions23. Samples were randomized across assay wells, chips 
and plates to prevent batch bias. Robotics handled the 450K BeadChips, which were analyzed 
using the Illumina Hi-Scan system. DNA methylation was assessed at 485,512 CpG sites. 
Probe signal intensities were extracted by Illumina GenomeStudio software (version 
XXV2011.1, Methylation Module 1.9) methylation module and background subtracted. A 
variety of quality assurance and control measures were implemented and have been previously 
described24, such as determination of assay repeatability and batch effects. The All Sample Mean 
Normalization (ASMN) algorithm24, adjusted for color channel bias, batch effects and 
differences in Infinium chemistry. Additionally, Beta Mixture Quantile (BMIQ) normalization 
was used to account for differences between the two Illumina probes25. Samples were retained if 
95% of sites assayed had detection P-values greater than 0.01. Criteria for removal included: 1) 
sites with annotated probe SNPs (n = 65) and with common SNPs (minor allele frequency >5%) 
within 50bp of the target identified in the MXL (Mexican ancestry in Los Angeles, California) 
HapMap population (n = 49,748); 2) sites mapped to the X (n = 10,708) and Y (n = 95) 
chromosomes14; 3) cross-reactive probes identified by Chen et al.26 (n = 26,950); and 4) probes 
where 95% of samples had detection P-values greater than 0.01 (n= 460). A total of 398,483 
CpG sites remained for analysis. Methylation beta values across sites were logit transformed to 
the M-value scale to more accurately adhere to modeling assumptions27. Methylation 
observations greater or less than three times the interquartile range for a given CpG site were 
removed prior to regression analyses to reduce the influence of methylation outliers. 
 
Statistical analysis 
To examine the distributions of individual metabolites in maternal blood during 
pregnancy, we computed descriptive statistics. We used Student’s T-tests to compare 
methylation profiles between CHAMACOS newborns with methylation data that were included 
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(N=81) and excluded (N=288) in the current analyses, with results indicating no significant 
differences in methylation between the two groups. There was no difference between the subset 
of the participants included in this study and the rest of the CHAMACOS cohort. 
To determine the relationship between maternal pregnancy metabolomics profiles as the 
exposure and 450K DNA methylation of their newborn children as the outcome, we fit limma 
linear models with empirical Bayes variance shrinkage28. In order to reduce the influence of 
metabolite outliers, all 92 maternal lipid metabolites were log(1+x) transformed. We adjusted for 
sex and batch in each of the models. Since DNA methylation has been observed to vary by cell 
type29, we also accounted for white blood cell type proportions in statistical models. To estimate 
cord blood proportions of 7 white blood cell types, including nucleated red blood cells, we 
utilized a cord blood reference dataset from Johns Hopkins30. We adjusted p-values for multiple 
hypotheses testing using the Benjamini-Hochberg (BH) false discovery rate (FDR) threshold for 
significance of 0.0531. We also identified CpGs that were significant based on the more 
conservative Bonferroni correction (uncorrected p value < 1.36 × 10−9 to account for 36,660,436 
tests). This analysis was performed using R statistical computing software (v3.5.1)32.  
 
Gene ontology analysis 
We used the online tool PANTHER (protein annotation through evolutionary 
relationship)33 to classify the function and relevant pathways of genes with FDR significant CpG 
sites related to lipid metabolites. Briefly, the list of genes was entered into the “Gene List 
Analysis” tool in PANTHER and the functional classification for each gene was generated. Gene 
ontology related to molecular function, biological process, cellular component, protein class, and 
pathway was available for most of the genes identified in the regression results. 
 
4.4 Results 
Study Population 
 Characteristics of CHAMACOS mothers and children included in the study are presented 
in Table 4.1. Additional data on CHAMACOS demographic parameters have been previously 
described19. Most mothers were overweight or obese (BMI ≥ 25 kg/m2) prior to pregnancy. 
Roughly equal portions of children were boys and girls, 5% were of low birth weight (<2500 g) 
and 7% born were premature (<37 weeks).  
 
Maternal Prenatal Metabolomic Profiles 
 In this study, we focused on maternal metabolites previously identified to be relevant to 
lipid biosynthesis, arachidonate enrichment and release, and inflammatory signaling18. The 92 
plasma metabolites in the study included fatty acids, lysolipids, phospholipids, sphingolipids, 
monoacylglycerols, diacylglycerols, and triacylglycerols (Table 4.2, Figures 4.1 and 4.2). 
Example distributions of specific fatty acid, lysolipid, and phospholipid metabolites are shown in 
Figure 4.1. Median lipid metabolite counts ranged from 0.01 (C16:0e/C18:1 PSe) to 44,132.92 
(C16:0/C18:1 PC) (Table 4.2). In Figure 4.2, we plotted the median values for the metabolites 
within each of the four quartiles based on the ranges in the metabolite distributions. The 
phosphatidylcholine (PC) phospholipids had the highest median values and a broad range across 
subjects. All metabolites were log(1+x) transformed in analyses in order to reduce the influence 
of outliers. 
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Maternal Metabolomics and Newborn DNA Methylation Analyses  
Numerous maternal prenatal metabolites were significantly associated, after correcting 
for multiple hypotheses testing, with DNA methylation of CHAMACOS newborns (Table 4.3). 
The metabolites that were related to newborn DNA methylation after adjusting for relevant 
covariates, indicated by an asterisk above the bar plots in Figure 4.2, were distributed across the 
four quartiles based on metabolite ranges, with four of the nine significant metabolites found in 
the lowest quartile of ranges (Figure 4.2A). After adjusting for child sex, batch, and white blood 
cell type estimates, 4 phospholipids (C16:0/C20:4 PS, C16:0e/C18:1 PSe, C18:0/C20:4 alkyl PA, 
C18:0e/C18:1 PEe), 4 lysolipids (C16:0 alkyl LPA, C18:1 alkyl LPA, C18:1 LPI, C20:4 LPS), 
and the fatty acid C18:0 FFA were among the significant metabolites related to newborn 
methylation. The number of CpG sites significantly associated with a specific metabolite ranged 
from 1 to 6. The phospholipid C18:0/C20:4 alkyl PA, shown in Figure 4.3, was one of two 
phospholipid metabolites associated with methylation at 6 different CpG sites, shown by the data 
points above the red genome-wide significance threshold. Prior to adjustment of p values for 
multiple hypotheses testing, this metabolite was associated with 10,338 CpG sites throughout the 
genome. Four of the FDR significant CpG sites associated with C18:0/C20:4 alkyl PA were also 
related to C18:1 LPI.  
Several CpG sites had significant relationships with one phospholipid (C18:0/C20:4 alkyl 
PA) and/or two lysolipid (C16:0 alkyl LPA, C18:1 LPI) metabolites (lysolipids are phospholipid 
breakdown products). For instance, cg12106728 was negatively associated with C18:0/C20:4 
alkyl PA (β=-1.014, FDR p=0.005) and C18:1 LPI (β=-1.667, FDR p=0.003).  A CpG site that 
maps to CTDSP2 and MIR26A2, cg17169243, was inversely related to C18:0/C20:4 alkyl PA 
(β=-0.454, FDR p=0.019), C18:1 LPI (β=-0.807, FDR p=0.002), and C16:0 alkyl LPA (β=          
-0.366, FDR p=0.021). cg19220754, located in the body of TNPO1, was hypomethylated with 
increased C18:0/C20:4 alkyl PA (β=-1.843, FDR p=0.019) and C18:1 LPI (β=-2.962, FDR 
p=0.019). cg24175823 was negatively associated with C18:0/C20:4 alkyl PA (β=-1.341, FDR 
p=0.002), C18:1 LPI (β=-2.039, FDR p=0.018), and C16:0 alkyl LPA (β=-1.024, FDR p=0.018). 
Out of the 28 total significant relationships between metabolites and CpG sites, 22 had negative 
regression coefficients, suggesting that increased lipidomic levels in maternal blood are generally 
associated with lower DNA methylation in their newborn children. 
Although most of the significant associations were negative, some of the positive 
relationships observed between maternal metabolite levels and infant DNA methylation had the 
largest effect sizes. A CpG site that maps to SEPT2 and HDLBP, cg16787284, was positively 
related to C16:0e/C18:1 PSe (β=25.723, FDR p=0.026) and C18:0e/C18:1 PEe (β=1.154, FDR 
p=0.021). cg22539279, located in NEK11 and ASTE1, was also hypermethylated with increased 
C16:0e/C18:1 PSe (β=23.200, FDR p=0.021). 
In addition, seven of the FDR-significant relationships remained after using the more 
stringent Bonferroni adjustment. These included the associations of cg10874881 and 
cg16597728 with the phospholipid C16:0/C20:4 PS, cg12106728 and cg24175823 with the 
phospholipid C18:0/C20:4 alkyl PA, cg21883754 with the phospholipid ether C16:0e/C18:1 PSe, 
and cg12106728 and cg17169243 with the lysolipid C18:1 LPI.  
 
Pathway Analysis of Gene Hits 
The maternal metabolites significantly associated with newborn methylation included 
complex lipids and products of lipid degradation, side products generated from choline and fatty 
		 41	
acid release for the developing fetus (Figure 4.4A and 4.4B). These lipids provide a methyl 
source for DNA methylation and drive growth, providing lipid building blocks and energy 
(Figure 4.4B). In order to determine the biological relevance of the metabolomic and methylation 
findings, we ran pathway analysis of the genes for which the significant CpG hits were mapped 
(Table 4.4). The most common molecular functions relevant to the genes included binding and 
catalytic activity. Additionally, the genes were involved in a range of biological processes at the 
cellular and metabolic levels and participated in biological regulation, response to stimulus, and 
localization. The genes BDNF, PC, and SEPT2 have been related to a variety of pathways, 
including Huntington disease, pyruvate metabolism, and Parkinson disease, respectively. 
 
4.5 Discussion 
 In this study, we characterized the lipidomic profiles of pregnant women from the 
CHAMACOS cohort, building upon previous research that identified associations of 
metabolomic data with phthalates, endocrine disrupting chemicals, and maternal pre-pregnancy 
BMI18. We focused on maternal metabolite levels assessed around 26 weeks gestation, rather 
than at child delivery, due to the availability of existing metabolomic data and more importantly, 
to better capture exposures relevant during fetal development that could relate to newborn 
epigenetic profiles. The 92 lipid metabolites assessed had broad ranges of levels in the women’s 
plasma. We further examined the relationship between maternal metabolite counts and offspring 
DNA methylation. Out of the lipid metabolites assessed, we identified significant and 
predominantly negative associations among four phospholipids, four lysolipids, and a fatty acid 
with newborn methylation. Additionally, several of the significant metabolites were related to 
multiple CpG sites. For example, the phospholipids C16:0/C20:4 PS and C18:0/C20:4 alkyl PA 
were both associated with 6 CpG sites. These results strengthen the evidence that maternal 
metabolites, particularly lysolipids and phospholipids, are related to reduced offspring DNA 
methylation at CpG sites in genes involved in a variety of biological processes, including 
catalytic and binding activities. 
The wide range in lipid metabolite levels observed in CHAMACOS is similar to a study 
conducted in 40 mother-child dyads from a clinical birth cohort in Michigan5. Marchlewicz et al. 
examined acylcarnitine, free fatty acid, and amino acid metabolite levels of mothers during the 
first trimester and at delivery, as well as of their children at birth. They observed wide 
distributions of free fatty acid levels similar to CHAMACOS, with medians ranging from 0.00 to 
152.70 nmol/mL and 0.00 to 247.90 nmol/mL for the maternal first trimester and delivery 
metabolites, respectively. In CHAMACOS mothers, median free fatty acid metabolite counts 
ranged from 1.12 to 4337.56. Higher levels in the CHAMACOS cohort could be attributed to 
differences in study populations; since CHAMACOS participants have a high prevalence of 
obesity and are Mexican-American as compared to the population in the Marchlewicz et al. 
study, which was mostly Caucasian; and the species of free fatty acid metabolites assessed in 
each cohort. 
In addition to determining the distributions of lipid metabolites in maternal plasma, 
another critical objective of the current study was to assess the relationship between maternal 
blood lipid levels and offspring DNA methylation at birth. Using a targeted approach, previous 
research in animal models has demonstrated associations between maternal fatty acid diet and 
increased DNA methylation of the fatty acid desaturase 2 (Fads2) gene in the liver of offspring, 
which encodes for Δ6 desaturase, a rate limiting enzyme in polyunsaturated fatty acid 
synthesis16, 17. A similar study in humans of the effect of fatty acid supplementation showed no 
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significant differences when comparing cord blood promoter methylation profiles of offspring of 
pregnant women receiving DHA or those in the placebo group34. Additionally, Sphingosine 1-
phosphate, a sphingolipid, has been linked at the cellular level to another epigenetic mechanism, 
histone acetylation35. 
Only a couple of studies have examined the association between blood lipid metabolite 
profiles and DNA methylation in humans. Petersen et al.6 assessed concurrent metabolomics 
profiles, including lipid metabolites, and DNA methylation levels in 1814 adults in Germany. 
Using methylation data measured by the Infinium HumanMethylation450 BeadChip platform, as 
used in the current study, and utilizing genome-wide SNP data, they were able to identify a 
significant and positive relationship, which also showed a strong genetic effect, between the 
phospholipid PC aa C38:4 and cg11250194. Additionally, several CpG site and metabolite 
associations were discovered after correcting for genetic effects, including a positive relationship 
between cg17901584 and the phospholipid PC ae C36:5. We also observed significant 
associations with phospholipid metabolite levels in the CHAMACOS cohort. Specifically, 
maternal levels of C16:0/C20:4 PS, C16:0e/C18:1 PSe, C18:0e/C18:1 PEe, and C18:0/C20:4 
alkyl PA were all related to newborn DNA methylation.  
In CHAMACOS, we observed predominantly negative relationships between maternal 
second trimester metabolite counts and newborn DNA methylation. Marchlewicz et al.5 
conducted a similar study in 40 predominantly white (85%) mothers and their children from 
Michigan. They examined whether maternal metabolomic profiles are associated with cord blood 
methylation globally, measured by LINE-1 and LUMA, and at genes relevant for growth, 
including the imprinted genes H19 and IGF2. They observed that maternal fatty acids measured 
during the first trimester were significantly and positively correlated with infant methylation at 
LINE-1, IGF2, ESR1, and PPARα, and negatively correlated with H19 and LUMA. Additional 
correlations were found for maternal delivery and cord blood metabolite levels with newborn 
methylation, with similar directions of association. Although we were not able to replicate the 
results observed in the Marchelwizc et al. study since they used a candidate gene approach, we 
were also able to observe a significant relationship between maternal lipid levels and imprinted 
gene methylation in newborns. Specifically, the relationship between cg27492749, a CpG site 
within another imprinted gene (SGCE), and the lipid metabolite C18:0/C20:4 alkyl PA. Taken 
together, these studies provide preliminary evidence of associations between maternal 
metabolomic environments during pregnancy and DNA methylation status of their offspring.  
Several of the genes with significant CpG sites related to maternal metabolite levels in 
the CHAMACOS cohort are involved in biological pathways associated with early life 
development. For instance, the BDNF gene encodes for the growth factor, brain-derived 
neurotrophic factor, which is important in the development of the central and peripheral nervous 
systems of infants36. Human septins, including the protein encoded by SEPT2, can assemble into 
higher-order cytoskeletal structures, such as filaments and bundles, which are necessary to the 
growing fetus37. Additionally, the PC gene encodes for the enzyme pyruvate carboxylase, which 
fuels the tricarboxylic acid cycle, the major pathway that drives the biosynthesis of amino 
acids38.  
The statistically significant lipids in the current study can be linked with DNA 
methylation in several ways. First, the process of lipid degradation releases fatty acids and 
lysolipids, as well as choline, which is transported to the developing infant. Choline serves as a 
major methyl source for DNA methylation and is also necessary for the synthesis of new 
biological membranes for rapidly dividing cells. The observed associations between DNA 
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methylation and lipid degradation products may be possible because the metabolic flux is 
relatively slow or their abundance is low. In contrast, we did not find associations for the 
phosphatidylcholine (PC) or triacylglycerol (TG) metabolites, which serve as major sources of 
either fatty acids or choline39, 40. The metabolic flux through PC and TG metabolism and their 
relative abundance is relatively high (Figure 4.2), which could obscure the association. Second, 
fatty acids provide a major energy source which drives growth in the developing fetus. Thirdly, 
ether lipids regulate cell differentiation and cellular signaling41. Ether lipids are an integral 
component of lipid membranes, provide enhanced integrity at lipid raft microdomains, and are 
important for membrane fusion and trafficking. 
A limitation of the present study includes the relatively small sample size, which could 
limit the power to detect significant differences based on the large number of tests performed. 
However, our study has more power than the most comparable study5, which has half the number 
of mother-child dyads with metabolomic and DNA methylation data. Another limitation is the 
absence of data on child metabolomic profiles at birth. However, given that maternal lipid 
metabolites can be transferred to the developing fetus via the placenta and that the prenatal 
period is a time of epigenetic remodeling, we feel that exploring the relationship between 
maternal metabolite levels during pregnancy, a sensitive time for epigenetic changes, is more 
relevant. Additionally, although DNA methylation is the most commonly studied epigenetic 
mechanism, maternal lipid metabolites could also be related to other epigenetic marks in 
children, including histone modifications.  
The main strengths of the current study include the use of multiple ‘omics’ data from the 
well-characterized CHAMACOS cohort, including the assessment of numerous classes of lipids, 
which expanded upon the fatty acids that have been previously assessed in relation to infant 
methylation data. This allowed for the discovery of novel associations between maternal 
metabolite levels, including phospholipids and lysolipids, and newborn DNA methylation, which 
could have implications on child health. Previous studies42, 43 in pregnant women with poor birth 
outcomes compared to controls revealed differences in metabolomic profiles of lipid metabolites. 
Additionally, lower levels of lysophospholipids, phospholipids, and monoacylglycerols during 
early pregnancy have been associated with macrosomia44. Epigenetics could be one mechanism 
whereby in utero exposure to maternal metabolites could impact health in early life. Future 
research should further explore the potential role of maternal metabolomic profiles on offspring 
DNA methylation and its role in child health.    
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4.8 Tables 
Table 4.1 Characteristics of CHAMACOS children and mothers (N=81 pairs) with newborn 
450K data and assessment of maternal metabolomic profiles at 26 weeks gestation 
Characteristics   
  N (%) 
Maternal age at delivery   
18-24 32 (39.5) 
25-29 36 (44.4) 
30-34 11 (13.6) 
35-45 2 (2.5) 
    
Newborn sex   
Boy 39 (48.1) 
Girl 42 (51.9) 
    
  Mean (SD) 
Maternal pre-pregnancy BMI (kg/m2) 25.5 (4.3) 
    
Newborn gestational age (weeks) 38.8 (1.7) 
    
Newborn birth weight (grams) 3413.1 (558.0) 
    
Newborn white blood cell count (%)   
Granulocytes 46.4 (10.3) 
CD4+ T 15.5 (6.7) 
CD8+ T 13.2 (3.8) 
B cells 9.5 (3.2) 
nRBC 10.4 (6.5) 
Monocytes 8.1 (1.9) 
NK cells 0.4 (1.2) 
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Table 4.2 Distribution of lipid metabolites in plasma of CHAMACOS mothers (N=81) 
Metabolite Pathway Median IQR 
C16:0/C18:1 DAG  Diacylglycerol 21.56 [14.44, 30.06] 
C16:0/C20:4 DAG  Diacylglycerol 0.91 [0.57, 1.35] 
C18:0/C18:1 DAG  Diacylglycerol 6.22 [3.83, 9.53] 
C18:0/C20:4 DAG  Diacylglycerol 0.07 [0.04, 0.12] 
C12:0 AC Fatty acid 1.12 [0.94, 1.41] 
C16:0 AC Fatty acid 25.18 [14.61, 40.10] 
C16:0 FFA Fatty acid 1660.35 [1282.00, 2199.70] 
C18:0 AC Fatty acid 8.19 [4.08, 11.94] 
C18:0 FFA Fatty acid 817.78 [664.32, 1159.16] 
C18:1 FFA Fatty acid 1109.79 [732.70, 1765.65] 
C20:4 FFA Fatty acid 2.96 [2.04, 3.78] 
DHA Fatty acid 232.88 [39.63, 752.88] 
Phytanic Acid Fatty acid 4337.56 [201.02, 10241.48] 
C16:0 alkyl LPA Lysolipid 0.46 [0.20, 0.85] 
C16:0 LPA Lysolipid 50.51 [40.01, 59.68] 
C16:0 LPE Lysolipid 0.28 [0.15, 0.61] 
C16:0 LPS Lysolipid 3.61 [2.37, 4.75] 
C16:0e LPCe  Lysolipid 59.15 [34.00, 85.07] 
C16:0e LPCe (lysoPAF) Lysolipid 122.48 [83.12, 171.97] 
C16:0e LPEe Lysolipid 3.51 [2.56, 4.35] 
C18:0 LPA Lysolipid 9.77 [7.42, 13.39] 
C18:0 LPE Lysolipid 1.47 [0.91, 2.80] 
C18:0 LPS  Lysolipid 0.11 [0.07, 0.17] 
C18:0e LPEe Lysolipid 15.59 [2.80, 24.27] 
C18:0e LPGe  Lysolipid 0.25 [0.02, 1.12] 
C18:1 alkyl LPA Lysolipid 0.54 [0.37, 0.73] 
C18:1 alkyl LPI Lysolipid 1.3 [0.62, 2.88] 
C18:1 LPE  Lysolipid 0.43 [0.21, 1.08] 
C18:1 LPI Lysolipid 0.12 [0.08, 0.17] 
C18:1 LPS  Lysolipid 0.41 [0.19, 0.57] 
C18:1e LPCe (lysoPAF)  Lysolipid 15.01 [2.96, 24.26] 
C18:1e LPEe Lysolipid 0.11 [0.07, 0.20] 
C20:0 LPC Lysolipid 13.84 [6.64, 19.75] 
C20:4 LPA Lysolipid 2.35 [1.68, 2.91] 
C20:4 LPC  Lysolipid 292.84 [196.19, 367.39] 
C20:4 LPS  Lysolipid 4.08 [3.60, 4.64] 
C20:4e LPSe Lysolipid 0.02 [0.01, 0.05] 
C16:0e MAGE Monoacylglycerol 255.78 [206.49, 327.70] 
C18:0 MAG Monoacylglycerol 154.63 [72.42, 199.03] 
C18:1 MAG Monoacylglycerol 35.7 [21.99, 64.30] 
C18:2 MAG Monoacylglycerol 6.14 [1.27, 12.82] 
C20:4 MAG Monoacylglycerol 0.47 [0.24, 0.88] 
C22:6 MAG Monoacylglycerol 0.05 [0.03, 0.09] 
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Metabolite Pathway Median IQR 
C16:0/C16:0 PI Phospholipid 1.9 [1.03, 3.60] 
C16:0/C18:1 PA Phospholipid 11.3 [10.35, 13.37] 
C16:0/C18:1 PC Phospholipid 44132.92 [37269.07, 52132.60] 
C16:0/C18:1 PI Phospholipid 12.26 [7.23, 20.11] 
C16:0/C20:4 PC Phospholipid 28780.3 [24703.64, 34127.57] 
C16:0/C20:4 PI Phospholipid 7.28 [4.30, 12.53] 
C16:0/C20:4 PS Phospholipid 0.04 [0.02, 0.07] 
C16:0e/C18:1 PCe Phospholipid 2154.21 [1889.12, 2520.64] 
C16:0e/C18:1 PEe  Phospholipid 0.75 [0.30, 1.02] 
C16:0e/C18:1 PSe Phospholipid 0.01 [0.01, 0.02] 
C16:0e/C20:4 PCe Phospholipid 2833.01 [2487.41, 3331.83] 
C16:0p/C20:4 PCp Phospholipid 1441.64 [1198.07, 1707.04] 
C18:0/C18:1 alkyl PA Phospholipid 4.04 [3.38, 4.59] 
C18:0/C18:1 alkyl PI Phospholipid 0.51 [0.30, 0.88] 
C18:0/C18:1 PA Phospholipid 35.8 [32.05, 42.42] 
C18:0/C18:1 PC Phospholipid 26515.68 [22344.95, 30784.37] 
C18:0/C18:1 PE  Phospholipid 0.05 [0.03, 0.09] 
C18:0/C18:1 PI Phospholipid 16.47 [9.57, 28.92] 
C18:0/C20:4 alkyl PA Phospholipid 0.82 [0.68, 1.05] 
C18:0/C20:4 alkyl PI Phospholipid 0.48 [0.30, 0.89] 
C18:0/C20:4 PA Phospholipid 3.23 [2.75, 3.96] 
C18:0/C20:4 PC Phospholipid 25368.63 [22167.33, 28643.58] 
C18:0/C20:4 PI Phospholipid 36.05 [21.71, 52.25] 
C18:0/C20:4 PS Phospholipid 0.61 [0.18, 0.91] 
C18:0e/C18:1 PCe Phospholipid 2440.81 [1981.18, 2796.77] 
C18:0e/C18:1 PEe  Phospholipid 0.7 [0.44, 1.18] 
C18:0e/C18:1 PGe Phospholipid 0.45 [0.03, 2.34] 
C18:0e/C20:4 PCe Phospholipid 4815.13 [4010.52, 5666.14] 
C18:0e/C20:4 PEe Phospholipid 0.09 [0.03, 0.16] 
C18:0p/C20:4 PCp Phospholipid 4569.48 [3835.01, 5374.80] 
C18:0p/C20:4 PEp Phospholipid 0.1 [0.04, 0.16] 
Cardiolipin C18:1/18:1/18:1/18:1 T2 Phospholipid 1.04 [0.80, 1.31] 
C16:0 Ceramide  Sphingolipid 12.11 [9.50, 13.92] 
C16:0 SM Sphingolipid 2178.44 [1830.64, 2544.65] 
C18:0 Ceramide  Sphingolipid 1.79 [1.37, 2.36] 
C18:0 SM Sphingolipid 1997.51 [1135.78, 2943.23] 
C18:0/C16:0 ceramide-1-phosphate Sphingolipid 8.26 [7.32, 10.12] 
C18:1 SM  Sphingolipid 2325.2 [2009.34, 2810.72] 
C18:1/C16:0 ceramide-1-phosphate Sphingolipid 92.51 [78.65, 109.94] 
C20:4 SM Sphingolipid 1400.77 [881.66, 1765.40] 
Lactosylceramide C18:1/C18:0 Sphingolipid 0.5 [0.28, 0.77] 
Sphinganine Sphingolipid 3.64 [1.38, 11.14] 
Sphingosine Sphingolipid 36.95 [19.04, 51.62] 
C16:0/C16:0/C16:0 TAG Triacylglycerol 1690.96 [958.05, 2779.60] 
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Metabolite Pathway Median IQR 
C16:0/C18:1/C16:0 TAG Triacylglycerol 10433.19 [7397.58, 13658.95] 
C16:0/C20:4/C16:0 TAG Triacylglycerol 3969.7 [2889.16, 5224.91] 
C18:0/C18:0/C18:0 TAG Triacylglycerol 216.26 [121.32, 356.69] 
C18:0/C18:1/C18:0 TAG Triacylglycerol 868.13 [430.36, 1782.46] 
C18:0/C20:4/C18:0 TAG Triacylglycerol 2.72 [1.61, 9.12] 
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Table 4.3 Significant results of the relationship between prenatal maternal metabolite levels in 
plasma and newborn cord blood DNA methylation 
CpG sites Chr N βa SE 
FDR        
P-
Value Significant Exposures Genes Gene Location 
Relation 
to CpG 
Island 
cg02496111 16 81 -3.172 0.467 0.012 C16:0/C20:4 PS - - Island 
cg03168497 17 81 -2.118 0.330 0.021 C18:1 alkyl LPA MYCBPAP Body Island 
cg04108939 1 80 1.169 0.187 0.039 C20:4 LPS BEST4 Body Island 
cg06494167 2 80 -1.428 0.214 0.018 C18:1 LPI RMND5A TSS1500 Island 
cg07370087 1 81 0.469 0.076 0.044 C18:0 FFA - - - 
cg08838610 17 81 -3.662 0.589 0.040 C16:0/C20:4 PS RPAIN, NUP88 TSS200, 1st Exon Island 
cg09931872 10 80 -2.409 0.365 0.018 C16:0/C20:4 PS WDFY4 5'UTR - 
cg10528455 2 81 0.492 0.076 0.019 C18:0/C20:4 alkyl PA - - - 
cg10874881 7 80 -2.546 0.346 0.002 C16:0/C20:4 PS POU6F2 Body - 
cg12106728 12 79 -1.014 0.144 0.005 C18:0/C20:4 alkyl PA - - Island 
  79 -1.667 0.229 0.003 C18:1 LPI    
cg14630692 9 81 -0.305 0.047 0.019 C16:0 alkyl LPA URM1 Body - 
cg14897096 11 78 -1.911 0.286 0.018 C16:0/C20:4 PS PC 5'UTR N_Shelf 
cg15710245 11 79 -0.731 0.114 0.024 C18:0e/C18:1 PEe BDNF TSS200, 
TSS1500, Body, 
5'UTR 
Island 
cg16597728 20 79 -2.063 0.293 0.005 C16:0/C20:4 PS APCDD1L Body S_Shore 
cg16787284 2 81 25.723 4.056 0.026 C16:0e/C18:1 PSe SEPT2, HDLBP TSS200, 5'UTR Island 
  81 1.154 0.180 0.021 C18:0e/C18:1 PEe    
cg17169243 12 79 -0.366 0.057 0.021 C16:0 alkyl LPA CTDSP2, MIR26A2 Body, TSS1500 - 
  79 -0.454 0.070 0.019 C18:0/C20:4 alkyl PA    
  79 -0.807 0.105 0.002 C18:1 LPI    
cg19220754 5 81 -1.843 0.281 0.019 C18:0/C20:4 alkyl PA TNPO1 Body Island 
  81 -2.962 0.456 0.019 C18:1 LPI    
cg21883754 19 79 -21.976 2.924 0.002 C16:0e/C18:1 PSe TTYH1 TSS200 N_Shore 
cg22539279 3 81 23.200 3.607 0.021 C16:0e/C18:1 PSe NEK11, ASTE1 TSS200 Island 
cg24175823 10 77 -1.024 0.154 0.018 C16:0 alkyl LPA - - Island 
  77 -1.341 0.180 0.002 C18:0/C20:4 alkyl PA    
  77 -2.039 0.306 0.018 C18:1 LPI    
cg27492749 7 76 -1.548 0.235 0.019 C18:0/C20:4 alkyl PA SGCE, PEG10 Body, TSS1500 Island 
Bolded FDR p-values indicate CpGs that were also significant based on the more conservative Bonferroni correction (uncorrected p value < 1.36 
× 10−9). Abbreviations: Chr, chtomosome. 
aRegression coefficients of the relationship between log(1+x) transformed maternal prenatal metabolites and newborn DNA methylation M 
values, adjusting for child sex, batch, and white blood cell composition. 
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Table 4.4 Pathway information for genes with CpG sites significantly associated with maternal 
metabolite levels. APCDD1L, MYCBPAP, POU6F2, URM1, and WDFY4 did not map to any 
pathway data in PANTHER. 
Gene Molecular Function Biological Process Cellular Component Protein Class Pathway 
BDNF Binding; Molecular 
Transducer Activity 
Biological 
Regulation; 
Cellular 
Component 
Organization or 
Biogenesis; 
Cellular Process; 
Multicellular 
Organismal 
Process; Response 
to Stimulus; 
Signaling 
Cell; Extracellular 
Region; Membrane; 
Organelle; Synapse 
Signaling 
Molecule 
Huntington 
Disease; 
Metabotropic 
Glutamate 
Receptor 
Group II 
Pathway 
BEST4       Transporter   
CTDSP2 Catalytic Activity        
NEK11   Cellular Process Cell; Organelle Transferase   
NUP88   Localization Cell; Organelle; 
Protein-Containing 
Complex 
Transporter   
PC Catalytic Activity Metabolic Process Cell  Ligase Pyruvate 
Metabolism 
RMND5A Catalytic Activity Metabolic Process Cell; Organelle; 
Protein-Containing 
Complex 
    
SEPT2 Binding; Catalytic 
Activity 
Cellular 
Component 
Organization or 
Biogenesis; 
Cellular Process; 
Localization 
Cell; Membrane; 
Protein-Containing 
Complex 
Cytoskeletal 
Protein; 
Enzyme 
Modulator 
Parkinson 
Disease 
SGCE Binding  Developmental 
Process 
 Calcium-
Binding Protein 
  
TNPO1 Binding; Transporter 
Activity 
Localization Cell; Membrane; 
Organelle 
Transfer/Carrier 
Protein; 
Transporter 
  
TTYH1 Transporter Activity  Cell Transporter   
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4.9 Figures 
Figure 4.1 Representative histograms of three lipid metabolite classes: A) a fatty acid, C18:0 
FFA; B) a lysolipid, C18:1 alkyl LPA; and C) a phospholipid, C18:0e/C18:1 PEe 
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Figure 4.2 Median levels of metabolites with ranges in the A) first (lowest), B) second, C) third, 
and D) fourth (highest) quartiles. An asterisk (*) above a metabolite name represents metabolites 
that were significantly associated with DNA methylation in newborns. 
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Figure 4.3 Manhattan plot of CpG sites of CHAMACOS newborns associated with C18:0/C20:4 
alkyl PA levels in the blood of their mothers during pregnancy. Red line represents genome-wide 
significance threshold of –log10(5.00E-08), while the blue line corresponds to the suggestive 
threshold of –log10(1.00E-05). 
 
 
 
 
 
 
Figure 4.4 Diagram of the significant positive (+) and negative (-) associations observed 
between maternal metabolites during pregnancy and newborn DNA methylation (A) and the 
biological pathways whereby maternal lipid levels could impact DNA methylation of their 
children (B).  
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CHAPTER 5. Early Life Home Environment and Obesity in a Mexican-American Birth 
Cohort: The CHAMACOS Study 
 
5.1 Abstract 
Background: Little is known about the impact of the home environment on biomarkers of 
obesity, such as adipokines, in children. In this study, we examined the relationship of maternal 
depressive symptoms and potentially protective social factors, including maternal support and 
the home learning environment, with BMI and adipokines. Methods: Data were obtained from 
326 Mexican American participants from the Center for the Health Assessment of Mothers and 
Children of Salinas cohort. Plasma adipokine levels were assessed in 326 children by enzyme-
linked immunoassay at birth or ages 5, 9, or 14. Maternal depressive symptoms were evaluated 
using the Center for Epidemiological Studies Depression Scale when children were 1, 3.5, 7, and 
9 years old; social support was assessed by the Duke-UNC Questionnaire at ages 1 and 5; and 
home learning environment by the Home Observation for the Measurement of the Environment 
(H.O.M.E.) at 6 months and 1, 2, 3.5, 7, 9, and 10.5 years. Results: Age was significantly 
associated with adiponectin (β=-5.0, standard error=0.2) and leptin (β=0.01, standard 
error=0.003) levels. Individual time point analyses identified significant positive associations of 
H.O.M.E. scores in childhood with adiponectin at ages 9 (H.O.M.E. score; age 3.5: β=0.9, 
p=0.04) and 14 (H.O.M.E. score; age 7: β=0.6, p=0.02, age 9: β=0.6, p=0.05, age 10.5: β=0.5, 
p=0.04). We observed significant relationships of maternal depressive symptoms at age 9 with 
adiponectin and BMI z-score at age 14 (β=-0.2, p=0.003 and β=0.02, p=0.002, resp.), which 
were confirmed in longitudinal models. Conclusions: This study adds new evidence that adverse 
and protective aspects of the home environment could lead to altered obesity status in children. 
 
5.2 Introduction 
Obesity is influenced by lifestyle, genetic, and environmental risk factors1 and remains a 
critical public health issue nationwide2, 3. The burden of the obesity epidemic falls 
disproportionately on minorities; specifically, Hispanic and non-Hispanic black youth have a 
higher odds of obesity compared to non-Hispanic white and Asian youth3. Children diagnosed as 
obese, based on body mass index (BMI) at or above the 95th percentile, have an increased risk of 
developing cardiovascular disease and diabetes later in life and to become obese as adults4, 5. 
 Increasing evidence suggests that early life measures of the home environment, including 
family stability, may influence risk of obesity6-8. Aspects of the home environment have also 
been associated with the production of biologically-active markers of obesity secreted by adipose 
tissue, including the adipokines: leptin and adiponectin9-11. The protein hormone adiponectin, 
which is primarily derived from adipose tissue, has anti-diabetic, anti-atherogenic, anti-
inflammatory, and insulin-sensitizing properties that mediate the pathogenesis of metabolic and 
cardiovascular disease12, 13. Studies in adults have shown inverse relationships between self-
reported early life measures of a poor home environment, including abuse, neglect, and 
household dysfunction, with adiponectin levels assessed in adulthood9, 11, 14. Additional research 
has reported lower adiponectin levels in adult subjects with depressive symptoms in comparison 
to controls15-17.  
Leptin, another adipokine, is a hormone predominantly secreted by adipose tissue and has 
also been found in other tissues such as ovaries, placenta, and the brain18, 19. Leptin can moderate 
energy homeostasis, which can be altered during depression, through interaction with central 
circuits in the hypothalamus16, 20. Similar to adiponectin, a number of studies in adults have 
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reported associations between leptin levels and early life family or home dysfunction9, 10, 14 and 
depressive symptoms in adulthood21. In contrast to adiponectin, the amount of leptin secreted 
into circulation is higher in adults who have experienced poor home environments or mental 
illness. However, the only prospective study to date in children22, utilizing data from 170 12-year 
old children from Great Britain, reported suggestive, yet insignificant lower levels of leptin in 
children exposed to early life maltreatment.   
In the Center for the Health Assessment of Mothers and Children of Salinas 
(CHAMACOS) cohort, we previously reported that 7-year old children whose mothers 
consistently demonstrated depressive symptoms had 2.4 times the adjusted odds of 
overweight/obesity compared to those whose mothers never experienced symptoms of 
depression23. Adipokine trajectories from birth to age 9 have been characterized in a subset of 
CHAMACOS participants, and have shown three distinct risk groups for each adipokine with 
complex age dynamics through childhood24. Thus far, studies on aspects of the home and family 
environment and adipokines have focused primarily on adult populations, are cross-sectional in 
nature, are predominantly conducted in African-American and White populations, and primarily 
are focused on symptoms of mental health and family dysfunction, rather than protective home 
environment factors.  
In the current study, we examine the relationship of maternal depressive symptoms, as 
well as the positive influences of social support and a healthy home environment, with BMI and 
adipokines in children from the CHAMACOS cohort, a Mexican-American birth cohort with 
high levels of childhood obesity25. We explored these specific psychosocial factors based on 
previous research that has provided preliminary evidence of how early life quality of the home 
environment26-28, maternal depression23, 29, and offspring social support30 can impact adiposity 
from infancy to adulthood, making use of available data measured at multiple time points in 
early childhood in the CHAMACOS cohort. We hypothesize that children who were raised in a 
better home environment with less stress and adversity, and whose mothers had better social 
support and exhibited fewer symptoms of depression, would have increased adiponectin levels 
and lower BMI and leptin levels through decreased activation of the hypothalamic-pituitary-
adrenal (HPA) axis, which can alter levels of hormones that impact obesity risk. We anticipate 
that recent and previous exposures to home environment factors will influence adipokines and 
obesity status, given the increasing awareness of how early life exposures can alter future disease 
risk. Furthermore, we expand our previous analysis of adipokines to a larger number of 
participants (n=326) and extend follow up from age 9 through age 14.  
 
5.3 Methods 
Study population 
CHAMACOS is a longitudinal cohort established to assess the health effects of 
environmental exposures, such as pesticides, on child growth and development31. A total of 601 
pregnant women were enrolled in the study between October 1999 and October 2000. Mothers 
enrolled in the CHAMACOS study were >18 years of age, <20 weeks gestation at enrollment, 
eligible for low income health insurance (Medi-Cal eligible), Spanish or English speaking, and 
intended to deliver at the county hospital. Of the 536 live births, the number of children with 
adipokine measurements at different time points were as follows: delivery (adiponectin, leptin; 
N=217, N=211), age 5 (N=227, N=201), age 9 (N=250, N=244), and age 14 (N=233, N=228). 
The total number of children included in this study was N=326, and most had adipokine data for 
more than three time points (Figure 5.1). 
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All study procedures were approved by the Committee for the Protection of Human 
Subjects at the University of California, Berkeley. Informed consent was obtained from all 
mothers; oral assent was obtained from children from age 7 to 11 years, and written assent was 
obtained starting at 12 years. 
 
Procedures 
 Women were interviewed at ~13 and ~26 weeks gestation, following delivery, and during 
the developmental assessments of the children at 6 months, 1, 2, 3.5, 5, 7, 9,10.5, and 14 years of 
age. To accommodate the study participants, questionnaires and assessments were administered 
in either English or Spanish by bilingual, bicultural interviewers. Information gathered at each 
interview included sociodemographic factors, health status, diet, and an assessment of exposure 
risk factors.  
Maternal depressive symptoms and protective factors, including social support and 
H.O.M.E scores, were measured throughout childhood and early adolescence in CHAMACOS 
participants. Maternal depressive symptoms were assessed using the Center for Epidemiological 
Studies Depression Scale (CES-D)32 when the children were 1, 3.5, 7, and 9 years old (Figure 
5.1). The recommended cutoff score of 1633 was used to identify mothers exhibiting symptoms 
of depression and the continuous CES-D scores (max range of 0-60, with a score of 60 
representing the worst possible score) were used in regression analyses. Social support was 
characterized in mothers at child age 1 and 5 years using the Duke-University of North Carolina 
Functional Social Support Questionnaire, with scores representing an average of responses on a 
1-5 scale to a validated eight-item instrument designed to measure functional social support. 
Higher scores indicate increased social support34. Characteristics of the home environment 
conducive to child development were determined at 6 months and 1, 2, 3.5, 7, 9, and 10.5 years 
of age using the Home Observation for the Measurement of the Environment (H.O.M.E.)35. For 
earlier visits (ages 6m – 2y), we used the Infant-Toddler H.O.M.E. inventory that combines 
observations of the home environment and mother child interactions by trained bilingual 
interviewers with questions about toys, books and the overall home learning environment that 
were asked of the mothers. The total H.O.M.E. scores are a combination of the responsivity, 
avoidance, learning and involvement subscales with a range of 16 – 45 points. At later time 
points (3.5y – 10.5y), we used a short-form of the H.O.M.E. inventory that was based only on 
maternal questionnaires that was comprised of emotional and cognitive subscales with a range of 
5 – 24 points. Higher social support and H.O.M.E. scores indicate more protective environments, 
whereas increased depression scale scores refer to more severe maternal depressive symptoms. 
Cronbach’s α, a measure of internal consistency, was 0.77, 0.57, and 0.79 for maternal 
depressive symptoms, social support, and H.O.M.E. scores, respectively, measured throughout 
childhood in the CHAMACOS cohort. 
Children were weighed and measured by trained research staff at ages 5, 9 and 14 years. 
We measured the children’s barefoot standing height to the nearest 0.1 cm using a stadiometer. 
Standing weight was measured to the nearest 0.1 kg using an electronic scale at age 5 (Tanita 
1582) and a foot-to-foot bioimpedence scale at ages 9 and 14 (Tanita TBF-300A Body 
Composition Analyzer). BMI was calculated as kg/m2. The CDC age- and sex-specific 
percentiles were used to categorize children as underweight, normal weight, overweight, or 
obese and BMI z-scores were used in analyses36.  
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Adipokine analysis 
 Adiponectin and leptin were assessed in blood specimens stored at -80°C collected from 
CHAMACOS participants at birth (cord blood), and repeatedly at 5, 9, and 14 years of age. We 
selected samples for analysis based on individuals with plasma available at a given 
CHAMACOS assessment. The subset of CHAMACOS participants used in this analysis was not 
significantly different from the main cohort in most demographic characteristics (child sex, 
baseline poverty, education, gestational age, parity, child overweight status). However, mothers 
in this sample tended to be slightly older at delivery and had higher average BMI than those not 
included in the analyses. Plasma adipokines were measured using enzyme-linked immunoassay 
(ELISA) RayBiotech Human Adiponectin and Human Leptin kits (RayBiotech Inc., Norcross, 
GA, USA). The protocol developed by the manufacturer was used, with some previously 
described modifications37 to increase precision for assessment in children: (a) the standard curve 
for adiponectin was narrowed in order to obtain better resolution at smaller readings, (b) the 
standard curve for leptin was broadened, and (c) plasma samples in the leptin analysis were more 
diluted. Final dilutions for the RayBio Human Leptin ELISA and the Human Acrp30 ELISA 
were 1:70 and 1:30,000, respectively. Absorbance values were obtained at a wavelength of 450 
nm, with an upper absorbance cutoff of 4.0 optical density units. The minimum detectable 
concentrations for adiponectin and leptin were 10 and 6 pg/mL, respectively. Internal lab 
controls were included on each plate to ensure reproducibility between the experimental runs, 
with average intra- and inter-plate CVs less than 5 and 14%, respectively.  All plasma samples 
were measured in duplicate.  
 
Statistical analysis 
 We log10 transformed leptin concentrations in CHAMACOS study participants for use in 
regression and correlation analyses since they were right-skewed. Adiponectin concentrations 
did not require this adjustment. The interrelationships between adiponectin and log-transformed 
leptin levels measured at birth and ages 5, 9, and 14 were assessed by Pearson correlation 
coefficients. Differences in mean adipokine levels by sex were determined by t-tests, and 
longitudinal trends of adipokines across childhood were characterized by generalized estimating 
equations (GEE) with an exchangeable correlation structure38. Since leptin demonstrated a 
difference by sex, we adjusted for sex in the GEE models with leptin as the outcome.  
Linear regression models with robust estimates of the standard errors were used to 
determine the association of continuous measures of maternal scores on the CES-D, HOME 
scores, and total social support scores with concurrent or future child adipokine levels and BMI 
z-scores, which were assessed at ages 5, 9, or 14. CES-D maternal depressive symptom, Duke-
UNC social support, and raw H.O.M.E. scores were assessed as continuous variables in 
regression models. We included additional covariates in the models that were identified in 
previous literature in CHAMACOS39 and in research assessing the relationship between 
adversity and obesity trends6.  
Specifically, two regression models were performed to assess the relationship between 
each independent home environment variable (i.e. continuous measures of maternal depressive 
symptoms, raw HOME scores, and total social support) and outcome (adiponectin, log-
transformed leptin, and BMI z-score): Model 1, the unadjusted model and Model 2, adjusting for 
child sex and maternal pregnancy variables. Maternal pregnancy variables in Model 2 included 
continuous (i.e. maternal pre-pregnancy BMI, years in the U.S., pregnancy sugar-sweetened 
beverage consumption per week), categorical (maternal education level, poverty status), and 
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binary (smoking and alcohol consumption) variables. The maternal education variable was coded 
as shown in Table 5.1. Maternal baseline poverty was coded as at or below poverty, greater than 
poverty to 200% of the poverty level, and greater than 200% of the poverty level. As a sensitivity 
analysis, we also ran Model 2 with an adjustment for poverty assessed concurrently with the 
outcome of interest (adipokines or BMI z-score). The results were similar to those of Model 2; 
thus, they were not presented in the tables. 
In addition, regression was used to assess the relationship between longitudinal trends of 
measures of the home environment and the outcomes (adipokines and BMI). We used GEE-
derived standard errors based on exchangeable working correlation models to provide robust 
inference in the presence of repeated measures. For both the maternal depressive symptom and 
H.O.M.E. scores, we generated a new variable by using the values for each that were measured 
at the same time or prior to the assessment of adipokines or BMI. Specifically, maternal 
depressive symptom measurements at child age 3 corresponded to obesity measurements at age 
5, and depressive symptoms at age 9 corresponded to adipokine and BMI measurements at ages 
9 and 14. We used the same time points for the H.O.M.E. score variable, with the exception of 
the correspondence of the 10.5 year H.O.M.E. score with the 14 year outcome assessment. We 
used social support values from the 5 year child assessment because it was the closest value for 
all time points of the outcomes. Henceforth, we will designate these variables as time varying 
measures of the home environment to distinguish them from the original variables. We used 
GEE models to assess the relationship between the time varying variables for maternal 
depressive symptoms, social support, or home environment and repeated measurements of 
adipokines and BMI from ages 5, 9 and 14. In the models, we adjusted for age and child sex, 
since they have been previously shown to influence adipokine and BMI trends and would be the 
most likely confounders in the current analysis. The following model was used: 
Yij = b0 + b1X1ij + b2X2ij + b3X3i + eij 
where Yij is either the BMI z-score or adipokine level for the i-th subject at the j-th 
anthropometric or adipokine assessment in childhood (j=5, 9, 14). X1ij is the time varying home 
environment value (i.e. H.O.M.E., social support, or maternal depressive symptom score) for the 
i-th subject and the j-th assessment, where j is time point of the home environment measurement 
that is either the same time as the adipokine or BMI assessment or the measurement prior. X2, X3 
and b2, b3 represent the covariates and their respective slopes for the age and child sex variables. 
eij is the residual error term. 
As a sensitivity analysis, we ran additional models, including one with all the time 
varying exposure variables (maternal depressive symptoms, H.O.M.E. score, and social support) 
and another model with poverty at outcome assessment. We also examined the potential of social 
support to moderate the relationship between home environment factors and obesity. We 
generated interaction terms by multiplying the maternal depressive or H.O.M.E. time varying 
scores by the social support variable, and included the new variable in analyses. We also ran 
mixed effect regression models to confirm GEE findings. Given the sample size, more 
complicated longitudinal models did not appear to have sufficient power to detect changes in 
measures of obesity related to previous or concurrent home environment parameters. 
 We controlled for the false discovery rate (FDR) in the analysis of individual 
assessments of measures of the home environment with child adipokines and BMI. All statistical 
analysis was performed in STATA (version 12.1, STATA Corp., College Station TX).  Statistical 
significance was set at p<0.05.      
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5.4 Results 
Study sample characteristics 
 Demographic and anthropometric data for CHAMACOS mothers and children (n=326) 
with adipokines assessed at least once during childhood (delivery or ages 5, 9, or 14) are shown 
in Table 5.1. At pregnancy, the majority of mothers were young, had lived in the United States 
for ten or fewer years, did not obtain a high school diploma, and had overweight or obesity. In 
our study, 48% of participants were boys and 52% were girls. More than half of the children at 
each time point had overweight or obesity: 53% of 5 year olds, 55% of 9 year olds, and 54% of 
14 year olds.    
 
Age and sex adipokine trends 
Adiponectin levels were highest at birth (mean ± SD, 101.2 ± 32.9 µg/mL) and were 
lower as children got older (age 5: 36.4 ± 16.2 µg/mL; age 9: 40.7 ± 18.1 µg/mL), and were 
lowest in adolescence (age 14: 23.7 ± 11.0 µg/mL) (Table 5.2, Figure 5.2). Leptin levels at birth 
were high (18.6 ± 18.7 ng/mL), which could indicate an influence of maternal levels of leptin. 
Leptin levels were much lower at age 5 (3.6 ± 3.3 ng/mL) and were higher as the children aged 
(age 9: 15.0 ± 16.7 ng/mL; age 14: 22.2 ± 17.2 ng/mL). Adiponectin levels did not vary by sex, 
with the exception of a borderline significant (p-value=0.049) difference at age 14 with higher 
levels in girls compared to boys (Table 5.2). Log leptin levels from delivery through age 14 were 
consistently higher in girls. Adiponectin levels were moderately and positively correlated across 
different time points, becoming stronger as children aged (Table 5.3). Adiponectin levels at a 
given time point were most correlated with measurements at adjacent time points (Table 5.3). 
Similar trends were observed in the leptin measurements. At each assessment, adiponectin levels 
were significantly and inversely associated with leptin levels, with the exception of delivery 
levels, when the negative trend was not significant (p-value=0.70) (Figure 5.3). Age was a strong 
predictor (p<0.001) of leptin and adiponectin levels in the GEE model. For adiponectin, β value 
was close to -5.0 (GEE β=-4.975, robust SE =0.153), and for leptin, β value was 0.013 (0.003), 
respectively.  
 
Maternal depressive symptoms and home environment protective factors  
 Among the mothers, 50%, 43%, 26%, and 26% were at risk of clinical depression with 
CES-D scores ≥16 when children were assessed at 12 months, 3.5 yrs, 7 yrs, and 9 yrs, 
respectively (Table 5.4). Scores reported at 12 months could also reflect symptoms of 
postpartum depression. Median maternal social support scores were high (1y: 4.0; 5y: 4.3). 
Median H.O.M.E. scores varied across the collections, reflective of the use of the Infant-Toddler 
H.O.M.E. inventory for earlier visits (ages 6m – 2y) and the short-form of the H.O.M.E. 
inventory for the later time points (3.5y – 10.5y). Specifically, median scores ranged from 26 to 
36 and 14 to 18 for the earlier and later visits, respectively. 
 
Individual assessments of measures of the home environment with child adipokines and 
BMI 
 We assessed the relationship of measures of the home environment across childhood at 
individual time points with obesity, as measured by BMI z-score, and adipokines. Maternal 
depressive symptoms at child ages 3.5 and 9 were positively associated with BMI z-score at ages 
9 and 14 (Table 5.5 and Supplemental Table 5.2). A one-unit increase in CES-D score when 
children were 3.5 and 9 corresponded to a 0.01-point increase in BMI z-score at age 9 (95% C.I.; 
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3.5yr: 0.003, 0.02; 9yr: 0.002, 0.02) and age 14 (95% C.I.; 3.5yr: 0.003, 0.02; 9yr: 0.006, 0.03). 
Social support and H.O.M.E. scores were not significantly associated with 9 yr BMI z-scores. 
However, a unit increase in social support at age 5 corresponded to a significant 0.2-point 
decrease in BMI z-score at age 14 (95% C.I.: -0.3, -0.05). Additionally, a one-unit increase in 
H.O.M.E. score at age 9 was associated with a 0.05-point decrease in BMI z-score at age 14 
(95% C.I.: -0.09, -0.005). The associations of maternal depressive symptoms at age 9 and social 
support at age 5 with BMI z-score at age 14 remained significant after FDR adjustment (all 
p<0.01). 
In models with adiponectin as the outcome, we observed a consistent trend across models 
of higher H.O.M.E. score, indicating a more enriched home environment, with increased 
adiponectin at age 9.  Positive associations with similar magnitudes of effect sizes were with 
H.O.M.E. scores at ages 3.5, 7, and 9, but only age 3.5 was significant in crude models, 
indicating that a one-unit increase in H.O.M.E. score at age 3.5 corresponded to a 0.9-point 
increase in adiponectin at age 9 (95% C.I.: 0.03, 1.8). Similarly, H.O.M.E scores were positively 
associated with adiponectin at age 14, with larger effect sizes observed in crude models with the 
7, 9, and 10.5 yr H.O.M.E. scores. Specifically, a one-unit increase in the total H.O.M.E. score at 
ages 7, 9, and 10.5 corresponded respectively to a 0.6-point increase (95% C.I.: 0.1, 1.2), 0.6-
point increase (95% C.I.: 0.001, 1.2), and a 0.5-point increase (95% C.I.: 0.02, 1.0) in 
adiponectin at age 14.  
We identified inverse associations of maternal depressive symptoms and 9yr adiponectin 
levels; however, results did not reach statistical significance. In the 14 yr adiponectin models, a 
one-unit increase in CES-D score when children were 7 and 9 corresponded to a 0.2-point 
decrease (95% C.I.; 7yr: -0.3, -0.03; 9yr: -0.3, -0.07) in adiponectin.  
Social support at age 5 had a positive relationship with adiponectin at age 9 and 14. 
Specifically, a one-unit increase in social support at age 5 corresponded to a 1.6-point increase in 
9yr adiponectin levels (95% C.I.: -0.9, 4.0), which was not significant but was similar in 
magnitude to a borderline significant 1.3-point increase in 14 yr adiponectin (95% C.I.: 0.003, 
2.7). For the adiponectin models, only the relationship between maternal depressive symptoms 
and adiponectin at age 14 remained significant after FDR adjustment (p=0.003). 
We also observed significant associations between symptoms of maternal depression, 
H.O.M.E. scores, and social support, predominantly in early childhood, and leptin levels in 
CHAMACOS children. In crude models, a one-point increase of maternal depressive symptoms 
at child age 3.5 corresponded to a 0.007-point increase in log leptin at age 9 (95% C.I.: 0.001, 
0.013), while a unit increase in scores at age 7 significantly related to a 0.007 increase in 14 yr 
log leptin levels (95% C.I.: 0.001, 0.013). A unit increase in H.O.M.E. score at age 2 
corresponded to a 0.03-point increase (95% C.I.: 0.003, 0.055) in log leptin levels at age 9. In the 
9 and 14 yr leptin models, the direction of association between social support and leptin was 
consistently negative.  
We also examined the relationship between positive and negative aspects of the home 
environment and adipokines at age 5 (Supplemental Table 5.1). Results were similar in 
magnitude to the 9 and 14 year adipokine and BMI models, but did not reach statistical 
significance, suggesting that obesity status and biomarkers of obesity in later childhood may be 
more sensitive to the effects of maternal depressive symptoms or protective home environment 
factors.  
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Longitudinal assessment of measures of the home environment with child adipokines and 
BMI 
Longitudinal models of adipokines and BMI z-score showed significant relationships 
with the most recent measures of maternal depressive symptoms and social support (Table 5.6). 
Maternal depressive symptoms were significantly associated with increased BMI z-score (β: 
0.007; 95% C.I.: 0.0004, 0.014) and decreased adiponectin (β: -0.248; 95% C.I.: -0.376, -0.119). 
Social support at age 5, which was the closest assessment to all childhood adipokine 
measurements (age 5, 9 and 14) was negatively associated with BMI z-score (β: -0.162; 95% 
C.I.: -0.273, -0.050) and leptin (β: -0.056; 95% C.I.: -0.096, -0.016). Cumulative H.O.M.E. score 
was not significantly associated with longitudinal levels of adiponectin across childhood (β:        
-0.285; 95% C.I.: -0.694, 0.124; p=0.17), contrary to the results observed in the individual 
models. In the sensitivity analysis, we found no significant differences in the model including all 
the exposure variables (maternal depressive symptoms, H.O.M.E. score, and social support) and 
another model with poverty at outcome assessment. The results of the analyses of a potential 
social support moderation of the relationships of H.O.M.E. score and maternal depressive 
symptoms with obesity indicated a lack of interaction. Mixed effect models produced similar 
results to the GEE models. 
 
5.5 Discussion 
In this longitudinal study, we examined adipokine levels and BMI throughout childhood 
and assessed their relationship with early life measures of the home environment in a Mexican-
American birth cohort. Adiponectin levels in CHAMACOS children were high at birth and, on 
average, lower as the children aged. Leptin levels were high at birth and during adolescence, but 
lower during early childhood (age 5). Previous mixture modeling analyses that reported 
trajectory clusters for adiponectin and leptin in a subset of CHAMACOS children up to age 9 
observed similar patterns in adipokine levels, including the large difference in adiponectin levels 
at birth and early childhood 24. We found consistent positive associations between H.O.M.E. 
score in late childhood and adiponectin at ages 9 and 14 indicating that a protective home 
environment is associated with beneficial profiles of adiponectin in children. Significant 
associations were observed between maternal depressive symptoms and H.O.M.E. score in early 
childhood and leptin at ages 9 and 14, but effect sizes were relatively small. We also report 
positive associations between maternal depressive symptoms at child age 3 and 9 with BMI z-
scores at ages 9 and 14, suggesting that increased maternal depressive symptoms are related to 
higher BMI z-scores in offspring. This data indicate that aspects of the home environment of 
CHAMACOS children could lead to altered obesity status and the expression of biomarkers of 
obesity. Clinical implications of these findings could include the direct impact of psychosocial 
factors on child health status and indirect effects, such as increased medical costs due to obesity 
comorbidities. 
In addition to previous adipokine trajectories research in the CHAMACOS cohort24, there 
have been only a few studies that have assessed trends of repeated measurements of adipokines 
throughout childhood. Mantzoros et al.40 examined the relationship between cord blood and 3 
year adipokine levels in 588 children in the Project Viva cohort. The authors found that while 
there was not a significant relationship between adiponectin levels at birth and age 3, leptin 
levels at the assessments were positively associated (crude model p=0.0003). Gruszfeld et al.41 
studied trends in adipokines in 459 children from infancy to age 8, observing a decrease in 
adiponectin and leptin levels from infancy, with an increase around school age for adiponectin 
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only. This finding is similar to our observations in the CHAMACOS cohort over a longer period 
from birth to 14 years of age. Another study in 519 Japanese children age 9 to 10 years old 
observed positive associations (p<0.001) between adipokine levels at baseline and values 
measured at the three-year follow-up42. In the current study, we also observed positive 
associations between adipokine assessments throughout childhood, with the strongest correlation 
observed for consecutive measurements. At each time point, we found leptin values were higher 
in girls compared to boys, which is consistent with previous reports42, 43. The sex difference 
observed for leptin, but not for adiponectin, could be a result of differences in body composition, 
as well as the potential of serum androgen levels to reduce the amount of leptin in boys44. 
In addition to assessment of trends in adipokine levels across childhood and by child sex, 
we examined the relationship of BMI, adiponectin, and leptin with maternal depressive 
symptoms and protective factors of the home environment, including social support and 
H.O.M.E. scores. Previous research has identified relationships of early life aspects of the home 
environment26-28, maternal depression23, 29, and offspring social support30 with obesity risk in 
offspring. In the CHAMACOS cohort, we identified consistent and positive associations between 
maternal depressive symptoms at child age 3 and 9 with BMI in adolescence. The positive 
relationship identified in the current study is similar to a previous study conducted by Audelo et 
al.23 in 332 7-year old CHAMACOS children, where youth whose mothers demonstrated 
depressive symptoms at the 1, 3.5 and 7 year child assessments had 2.4 times the adjusted odds 
of overweight/obesity relative to those whose mothers never experienced symptoms of 
depression. A similar study29, including 1,090 children with anthropometric assessments at 3 
time points during early childhood, reported that children with mothers exhibiting depressive 
symptoms, assessed by CES-D when the child was 1 month, as well as 2 and 3 years old, were 
1.7 times more prone to be overweight than their counterparts whose mothers did not report 
depressive symptoms. Taken together, these studies suggest a possible role of maternal 
depression in offspring obesity status and a potential avenue for obesity intervention.  
Most of the research regarding the relationship between adversity and adipokine 
measurements has been conducted in cross-sectional assessments of adult populations. Positive 
associations were found between abuse, family instability, and depressive symptoms, in early 
childhood or adulthood, and adult leptin levels9, 10, 21, 45, whereas negative relationships were 
observed between home and family measures and adiponectin in adulthood9, 11, 15-17, 46. In our 
prospective analysis in Mexican-American children, we also saw positive associations between 
maternal depressive symptoms and leptin levels throughout the child’s youth, and negative 
associations with adiponectin, particularly in older children. In addition, the positive associations 
we observed between H.O.M.E score and adiponectin at 9 and 14 years concurs with trends seen 
in the literature; in this case, as H.O.M.E. scores decrease, indicating poor home learning 
environment, adiponectin levels decline. Since adiponectin has many beneficial immunological 
and metabolic properties, a profile of lower levels is less desirable. The association between 
H.O.M.E. scores and adiponectin in the longitudinal models did not reach statistical significance 
(p=0.17); and thus, was unable to completely corroborate the individual time point findings.  
Although the current study relies on maternal assessment of adversity as children age into 
adolescence, it is plausible that maternal depressive symptoms, social support, and home 
environment could impact mental well-being, and biomarkers of obesity, of their children 
through several pathways. Numerous studies have demonstrated associations between stress and 
depressive symptoms in mothers and altered risk of obesity in their children, potentially 
mediated by parenting behaviors (i.e. through unhealthy dietary practices or sedentary lifestyles) 
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or parent-child interactions47-50. Maternal stress can induce a subsequent stress response in their 
children, as a result of augmented levels of cortisol51. In addition, pervasive stress during 
childhood has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, resulting in 
the release of hormones such as glucocorticoids that have downstream effects on obesity risk52. 
The biological pathways whereby family instability, stress, and depression in an 
individual can affect their adipokine profiles are well-documented in humans. As an anti-
inflammatory adipokine, adiponectin can inhibit the function of macrophages and tumor necrosis 
factor-α, and increase the secretion of anti-inflammatory cytokines, including interleukin-10 and 
interleukin-1 receptor antagonist53-55. However, during symptoms of depression, pro-
inflammatory cytokines, such as interleukin-6, can alter HPA activity, releasing glucocorticoids 
that can prevent adiponectin from exerting its anti-inflammatory effects56. Conversely, 
glucocorticoid secretion as a response to stressors enhances the production of leptin in humans57, 
58.  
The main strengths of the current study include the use of data collected longitudinally to 
assess the relationship between maternal depressive symptoms, social support, and the home 
environment and adipokine trends in a well-characterized Mexican-American birth cohort. 
Understanding the relationship between the home environment and biomarkers of obesity in this 
population is particularly relevant due to the high prevalence of both parental pre-pregnancy and 
childhood obesity. However, we recognize certain limitations, since we did not examine more 
data on child behavior, adverse experiences, and emotional well-being, which could mediate the 
relationship between maternal psychosocial factors and child obesity risk. In addition, other 
home environment factors that were not examined in the current study, such as single parent 
household and crowding, could influence adipokine levels in children. Given the projected 
growth in the Hispanic population in the United States59 and the high prevalence of obesity in 
Mexican-American children3, which we have observed in the CHAMACOS cohort, this research 
can have health implications in the general population and in minority populations at high risk of 
obesity. This study provides novel support for the relationship between early life exposure to 
maternal depressive symptoms and protective factors, such as social support and an enriching 
home environment, and their association with adipokines. This research can inform potential 
public health strategies to address early childhood factors that contribute to the obesity epidemic 
and comorbidities of obesity. 
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5.8 Tables 
Table 5.1 Demographic characteristics of CHAMACOS mothers and children with adipokine 
data at delivery or age 5, 9, or 14 years (n=326) 
Characteristic N (%) 
Maternal age at pregnancy   
18-24 134 (41) 
25-29 107 (33) 
30-34 54 (17) 
35-45 31 (10) 
    
Number of years mother lived in US at pregnancy   
Less than 1 year 57 (17) 
1-10 years 174 (53) 
11 or more years 95 (29) 
    
Parity   
0 105 (32) 
≥ 1 221 (68) 
    
Education   
≤ 6th grade 144 (44) 
7-12th grade 115 (35) 
≥ High school graduate 67 (21) 
    
Maternal pre-pregnancy BMIa   
Underweight (< 18.5 kg/m2) 2 (1) 
Normal (18.5-24.9 kg/m2) 112 (34) 
Overweight (25-29.9 kg/m2) 127 (39) 
Obese (≥ 30 kg/m2) 84 (26) 
    
Child sex   
Boy 155 (48) 
Girl 171 (52) 
    
Gestational age   
34-36 weeks 23 (7) 
≥ 37 weeks 303 (93) 
    
Child birthweight   
Low birthweight (< 2500 g) 12 (4) 
Normal birthweight (≥ 2500 g) 314 (96) 
    
Child 5 year BMI (CDC categories)a   
Normal (<85 percentile) 139 (47) 
Overweight (≥85 percentile, < 95 percentile) 61 (20) 
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Characteristic N (%) 
Obese (≤ 95 percentile) 98 (33) 
    
Child 9 year BMI (CDC categories)a   
Normal (<85 percentile) 134 (45) 
Overweight (≥85 percentile, < 95 percentile) 50 (17) 
Obese (≤ 95 percentile) 114 (38) 
    
Child 14 year BMI (CDC categories)a   
Normal (<85 percentile) 136 (46) 
Overweight (≥85 percentile, < 95 percentile) 56 (19) 
Obese (≤ 95 percentile) 103 (35) 
aTotal number of observations for BMI varies due to missing data 
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Table 5.2 Plasma adipokine levels at delivery and ages 5, 9, and 14 
  N Mean SD Min Max P-value 
Adiponectin (µg/mL)             
Delivery             
Boys 103 97.7 30.3 2.5 163.0 0.14 Girls 114 104.3 34.9 7.4 186.9 
All 217 101.2 32.9 2.5 186.9   
              
Age 5             
Boys 105 35.5 15.9 0.1 86.1 0.46 Girls 122 37.1 16.5 3.9 97.4 
All 227 36.4 16.2 0.1 97.4   
              
Age 9             
Boys 119 40.6 19.2 8.2 93.3 0.92 Girls 131 40.8 17.2 2.8 92.4 
All 250 40.7 18.1 2.8 93.3   
              
Age 14             
Boys 107 22.2 11.9 5.5 57.7 0.049 Girls 126 25.0 10.2 4.4 47.6 
All 233 23.7 11.0 4.4 57.7   
              
Leptin (ng/mL)             
Delivery             
Boys 98 13.7 15.0 1.9 84.6 <0.001 Girls 113 22.8 20.5 1.4 97.1 
All 211 18.6 18.7 1.4 97.1   
              
Age 5             
Boys 82 3.0 2.3 0.2 16.4 0.073 Girls 119 4.1 3.7 0.3 22.2 
All 201 3.6 3.3 0.2 22.2   
              
Age 9             
Boys 113 11.4 12.2 0.9 66.1 0.017 Girls 131 18.1 19.3 0.7 93.3 
All 244 15.0 16.7 0.7 93.3   
              
Age 14             
Boys 102 14.2 13.7 0.4 55.4 <0.001 Girls 126 28.6 17.1 2.8 73.8 
All 228 22.2 17.2 0.4 73.8   
P-values obtained from t-tests comparing adipokine levels in boys and girls at different 
assessments. SD=standard deviation, Min=minimum, Max=maximum 
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Table 5.3 Pearson correlation matrix of adipokines assessed at delivery and ages 5, 9, and 14 
  A0 A5 A9 
A5 0.26 - - 
A9 0.26 0.49 - 
A14 0.21 0.35 0.52 
  
     L0 L5 L9
L5 0.19 - - 
L9 0.37 0.51 - 
L14 0.28 0.35 0.56 
Bolded values are significant at p<0.05 
A0= adiponectin at delivery, A5= adiponectin at age 5, A9= adiponectin at age 9, A14= 
adiponectin at age 14, L0= log-transformed leptin at delivery, L5= log-transformed leptin at age 
5, L9= log-transformed leptin at age 9, L14= log-transformed leptin at age 14 
 
 
 
 
 
Table 5.4 Distribution of home environment parameters in CHAMACOS participants 
Adversity Parameter Child Age N Mean SD Min Max 
Maternal Depressive Symptoms (CES-D) 1 yr 301 16.7 11.0 0.0 50.0 
  3.5 yr 291 15.0 10.9 0.0 49.0 
  7 yr 308 10.8 9.5 0.0 43.0 
  9 yr 278 10.5 10.4 0.0 46.0 
  
      Duke Social Support 1 yr 303 3.8 1.0 1.0 5.0 
  5 yr 299 4.0 1.0 1.1 5.0 
  
      Total H.O.M.E Score 6 mo 325 31.8 4.3 16.0 43.5 
  1 yr 325 35.6 3.3 19.3 43.5 
  2 yr 325 25.8 2.7 13.3 31.0 
  3.5 yr 325 17.2 2.4 11.1 23.9 
  7 yr 319 17.7 2.8 9.0 24.0 
  9 yr 307 14.3 2.8 5.0 20.0 
  10.5 yr 298 14.5 2.8 6.0 20.0 
SD=standard deviation, Min=minimum, Max=maximum, CES-D=Center for Epidemiological 
Studies Depression Scale, HOME=Home Observation for the Measurement of the Environment 
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Table 5.6 Results of GEE analyses of the relationship of longitudinal trends in aspects of the 
home environment with adipokines or body mass index z-score 
Exposure   Outcome   β1 (95% Confidence Interval) 
Depressive Symptoms   BMI z-score   0.007 (0.0004, 0.014) 
    Adiponectin    -0.248 (-0.376, -0.119) 
    Log Leptin   -0.0004 (-0.004, 0.003) 
          
Social Support   BMI z-score    -0.162 (-0.273, -0.050) 
    Adiponectin   1.191 (-0.236, 2.618) 
    Log Leptin    -0.056 (-0.096, -0.016) 
          
H.O.M.E. score   BMI z-score   -0.002 (-0.022, 0.018) 
    Adiponectin   -0.285 (-0.694, 0.124) 
    Log Leptin   -0.009 (-0.021, 0.003) 
1Coefficient from GEE models adjusting for age and sex 
Bolded values are significant at p<0.05 
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5.9 Figures 
Figure 5.1 Schematic of analysis. 
 
 
 
 
Figure 5.2 Box plots of adipokine trends in CHAMACOS newborns and children at ages 5, 9, 
and 14 years old. The figure presents distributions of adipokines in all subjects with data 
available at each time point. In addition, GEE models were used to model longitudinal changes 
in adipokines by age. Age was a significant predictor of adipokine levels (p<0.001 for all 
models) for leptin and adiponectin. 
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Figure 5.3 The relationships between leptin and adiponectin in CHAMACOS children at birth 
and age 5, 9, and 14. The figure shows the relationship between adiponectin and leptin 
measurements at a given assessment. At all time points, with the exception of birth, leptin and 
adiponectin are significantly and inversely associated. 
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5.10 Supplementary Materials 
Supplementary Table 5.1 Relationship of aspects of the home environment during childhood 
with adipokines or body mass index z-score at age 5 
  β1 (95% Confidence Interval) 
  Depression Scale Duke SS 
  1Y 3Y 1Y 5Y 
BMI z-score         
Model 1 0.006 (-0.006, 0.018) 0.008 (-0.002, 0.018) 0.017 (-0.113, 0.147) -0.102 (-0.233, 0.030) 
Model 2 0.004 (-0.009, 0.016) 0.004 (-0.007, 0.015) 0.024 (-0.109, 0.157) -0.098 (-0.239, 0.043) 
          
Adiponectin         
Model 1 -0.063 (-0.250, 0.125) -0.155 (-0.351, 0.040) 0.014 (-2.315, 2.342) 0.055 (-1.950, 2.060) 
Model 2 -0.016 (-0.222, 0.189) -0.107 (-0.326, 0.112) 0.29 (-2.341, 2.922) 0.161 (-2.003, 2.325) 
          
Leptin         
Model 1 0.001 (-0.004, 0.005) -0.002 (-0.006, 0.002) -0.002 (-0.050, 0.046) -0.040 (-0.089, 0.009) 
Model 2 -0.0004 (-0.006, 0.005) -0.003 (-0.008, 0.002) 0.005 (-0.046, 0.055) -0.038 (-0.093, 0.016) 
          
  H.O.M.E. Score 
  6M 1Y 2Y 3Y 
BMI z-score         
Model 1 -0.004 (-0.030, 0.022) -0.012 (-0.052, 0.027) 0.008 (-0.044, 0.061) -0.018 (-0.067, 0.030) 
Model 2 -0.006 (-0.038, 0.026) -0.003 (-0.045, 0.040) 0.016 (-0.041, 0.074) -0.023 (-0.073, 0.026) 
          
Adiponectin         
Model 1 0.137 (-0.280, 0.553) 0.099 (-0.492, 0.691) -0.062 (-0.870, 0.747) 0.378 (-0.575, 1.331) 
Model 2 0.183 (-0.309, 0.675) 0.227 (-0.437, 0.892) 0.398 (-0.465, 1.261) 0.553 (-0.414, 1.520) 
          
Leptin         
Model 1 -0.003 (-0.012, 0.006) -0.001 (-0.014, 0.013) -0.007 (-0.027, 0.012) 0.012 (-0.007, 0.031) 
Model 2 -0.003 (-0.014, 0.008) 0.004 (-0.011, 0.019) -0.005 (-0.028, 0.017) 0.013 (-0.006, 0.031) 
1Linear regression coefficient 
Model 1: crude 
Model 2: crude + sex + smoking + alcohol + education + pre-preg bmi + preg ssb + baseline 
poverty + years US  
Bolded values are significant at p<0.05 
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CHAPTER 6. CONCLUSIONS 
 
 The epidemic of obesity has a high economic and health burden on society. Identifying 
additional risk factors for pediatric obesity beyond unhealthy diet and lack of exercise is 
especially critical considering the numerous co-morbidities and increased risk of obesity in 
adulthood. Understanding how environmental exposures can impact human health and epigenetic 
mechanisms is essential. DNA methylation is of particular interest since this epigenetic 
mechanism is involved in numerous biological processes, including imprinted gene control, and 
altered DNA methylation has been associated with numerous diseases. One of the main goals of 
this dissertation was to explore whether exposures during pregnancy, specifically to phthalates 
and lipid metabolites, are related to DNA methylation levels in newborns. The use of 
metabolomic data expanded our ability to characterize exposure to numerous metabolites in 
biological samples, which is a large improvement compared to traditional exposure methods and 
is more aligned with the goals of exposomics research. We were particularly interested in lipid 
and phthalate metabolites for their potential associations with obesity. Another objective was to 
determine if the home environment during childhood is associated with obesity risk, as measured 
by child BMI status and adipokine levels.  
We examined these relationships in the CHAMACOS cohort, which includes mothers 
and children followed for almost 20 years with extensive information on health and exposures, 
over 350,000 banked biological samples, and a high prevalence of obesity. Using multiple omics 
platforms including epigenomics, metabolomics, and molecular markers of obesity and oxidative 
stress, we addressed key knowledge gaps in the associations between environmental exposure, 
DNA methylation, and obesity risk, which are described below.  
• Research in humans on the relationship between phthalate exposure in utero and DNA 
methylation of imprinted genes, many of which are involved in early growth, has been 
limited to two imprinted genes (H19 and IGF2) and has only been examined in placenta 
samples1, 2. We assessed the relationship between prenatal phthalate exposure and 
methylation of nine imprinted gene differentially methylated regions in 296 
CHAMACOS newborns. Average pregnancy concentrations of metabolites of di-2-
ethylhexyl phthalate (DEHP) were significantly and positively associated with 
methylation at the MEG3 DMR. This is the first study to demonstrate that maternal 
urinary metabolites of DEHP, which is a chemical commonly added to plastics to 
increase flexibility, was linked to methylation profiles of children at birth in MEG3, a 
gene associated with early growth, tumorigenesis, and diabetes. Additionally, it is the 
only study that has examined this relationship in cord blood, which is more reflective of 
the fetal methylome. This research adds to the growing body of evidence of the health 
effects of phthalates and demonstrates a potential mechanism, imprinted gene 
methylation, whereby exposure can contribute to altered birth outcomes and future 
disease development. CHAPTER 3  
• Animal models have identified relationships between maternal dietary supplementation 
with fatty acids and offspring methylation status3, 4. A single study in a small, primarily 
Caucasian cohort from Michigan reported associations between prenatal exposure to lipid 
metabolites and DNA methylation profiles in newborns5. Using targeted metabolomics, 
we significantly expanded this line of discovery and identified a significant relationship 
between a prenatal fatty acid metabolite and newborn methylation. Although most of the 
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existing research has focused on fatty acids, we were able to uncover novel associations 
between maternal phospholipid and lysolipid levels and DNA methylation at delivery. In 
general, higher lipid metabolites during pregnancy were related to lower methylation 
levels at CpG sites mapped to genes involved in fetal development. The study is one of 
the first to show that numerous classes of maternal lipid metabolites, which can cross the 
placenta and act as biomarkers of exposure, are related to infant methylation in humans. 
Since the prenatal period is a particularly sensitive period for epigenetic structuring of the 
fetus, exposure to maternal lipid levels could shape expression of genes necessary for 
development via alteration of DNA methylation. CHAPTER 4  
• Previous research has identified relationships of early life home environment6-8, maternal 
depression9, and social support10 with infant or child adiposity. Additionally, increasing 
evidence suggests that family, home, and individual mental stability may impact the 
levels of biologically-active markers of obesity secreted by adipose tissue, including the 
adipokines: leptin and adiponectin11-20. However, research was generally limited to 
populations of African-American and White adults, was cross-sectional in nature, and 
focuses on the role of potentially detrimental psychosocial parameters, instead of 
protective factors such as social support and home learning environment. In our 
longitudinal study of Mexican-American children, we assessed the contribution of the 
home environment, perceived social support, and maternal depressive symptoms on 
childhood obesity risk. We observed that increased maternal depressive symptoms in 
early childhood were associated with higher BMI Z-score and leptin and lower 
adiponectin in adolescents. On the contrary, greater home enrichment was related to 
lower 14 year BMI Z-scores and higher adiponectin. Results were similar comparing 
early life home environment parameters with obesity status at age 9. One of the strengths 
of this research is the use of adipokines, which are recognized biological markers of 
obesity and help to understand aspects of the metabolic health status of an individual that 
are not captured by BMI. Using a molecular epidemiology approach, we generated 
stronger evidence that targeting mothers exhibiting symptoms of depression and 
enhancing the home learning environment may help prevent childhood obesity. 
CHAPTER 5 
 The concept of the Developmental Origins of Health and Disease postulates that 
exposures during tissue and organ development can influence future disease risk. In this 
dissertation, we have addressed knowledge gaps of the relationships of prenatal exposure to 
phthalates, chemicals found ubiquitously in humans, and maternal lipid metabolites with 
newborn DNA methylation. Emerging and exciting omics technologies, such as metabolomics, 
epigenomics, and molecular biomarkers, enabled us to make new discoveries regarding the role 
of the environment in shaping methylation profiles at genes important in early growth, with 
potential implications for children’s environmental health. The results highlight the importance 
of multi-faceted intervention strategies that account for environmental, biological, and 
psychosocial risk factors in obesity prevention. 
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CHAPTER 7. FUTURE DIRECTIONS 
 Understanding the molecular modifications that result from environmental exposure, 
particularly during the sensitive period of gestation, is essential for disease prevention. DNA 
methylation, an epigenetic mechanism that has been shown to relate to both exposures and health 
status, may be one pathway through which environmental exposures exert their effect. In this 
dissertation, we have examined the interplay between chemical and psychosocial exposures, 
DNA methylation of newborns, and pediatric obesity. Key future directions that build upon this 
research include: 
• Determination of the role of postnatal phthalate exposure on DNA methylation 
patterns. It will be critical to assess the relationship between childhood phthalate 
exposure and DNA methylation, both across the human genome and in targeted 
assessment of imprinted genes, many of which are involved in biological pathways 
important in growth. Since phthalates are known endocrine disrupting chemicals and we 
have observed in the CHAMACOS cohort that early life exposure is associated with 
persistent effects on childhood obesity risk, it is essential to understand the role of 
exposure to these chemicals on children as they develop through puberty, a period of 
hormonal shifts. 
• Assessment of the relationships between biological, parental, and environmental 
parameters on DNA methylation at later time points (i.e. 5, 9, and 14 yr) in the 
CHAMACOS children. Much of the current research in CHAMACOS and as part of the 
Pregnancy and Child Epigenetics (PACE) consortium focuses on the effects of early life 
exposure on newborn methylation. Given the availability of methylation data at later time 
points in the CHAMACOS cohort, it will be important to verify if changes in methylation 
profiles observed at birth persist as children age, and to determine whether age and other 
environmental exposures can impact certain areas of the human genome that are more 
relevant as children transition into adolescents. 
• Characterization of the effect of maternal stress and home environment on DNA 
methylation of newborns. Most of the existing research on the relationship between 
maternal stress and offspring DNA methylation has utilized a targeted approach. As part 
of the PACE consortium, we are interested in examining how maternal stressful life 
events can impact offspring DNA methylation. Given the observed associations described 
in this dissertation of maternal depression, perceived social support, and home learning 
environment with obesity risk in children, we would also like to make use of this wealth 
of data in the CHAMACOS cohort to assess the impact of maternal well-being and home 
environment on newborn and child methylation, and whether epigenetic mechanisms 
mediate the relationship between early life environment and child obesity risk.   
• Exploration of the interplay between environmental exposures and health effects 
using novel omics technologies. New technology continues to develop in order to keep 
pace with the expanding omics disciplines, particularly epigenomics. One of the 
promising new areas of research includes assessment of 5-hydroxymethylcytosine, a 
marker of demethylation of DNA. Using existing pilot 5-hydroxymethylcytosine in 
CHAMACOS newborns, we plan to explore the relationship between early life exposures 
and demethylation of DNA. We are also interested in examining additional epigenetic 
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markers, such as miRNAs and histone modifications, and how they are affected by 
environmental exposure. 
• Validation of findings. The results described in this dissertation would benefit from 
validation in animal models and in other cohorts, such as those of the PACE consortium. 
PACE includes researchers and study participants around the world and has a focus on 
early life environmental impacts on human disease using DNA methylation in newborns 
and children. As a member of PACE, we have explored numerous knowledge gaps of the 
effects of environmental exposure on child epigenetics, including the impact of maternal 
BMI, maternal smoking, and additional projects that will yield high impact publications. 
 
